US20040249365A1 - Implantable osmotic pump - Google Patents
Implantable osmotic pump Download PDFInfo
- Publication number
- US20040249365A1 US20040249365A1 US10/685,291 US68529103A US2004249365A1 US 20040249365 A1 US20040249365 A1 US 20040249365A1 US 68529103 A US68529103 A US 68529103A US 2004249365 A1 US2004249365 A1 US 2004249365A1
- Authority
- US
- United States
- Prior art keywords
- pump
- compartment
- pharmaceutical agent
- patient
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7527—General characteristics of the apparatus with filters liquophilic, hydrophilic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
- A61M5/14526—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons the piston being actuated by fluid pressure
Definitions
- the present invention relates generally to the field of drug delivery systems.
- the present invention relates to implantable osmotic pump systems.
- Subcutaneous drug delivery and intravenous drug delivery have the advantage of bypassing the acidic and enzymatic action of the digestive system.
- IV administration requires the use of a percutaneous catheter or needle to deliver the drug to the vein.
- the percutaneous site requires extra cleanliness and maintenance to minimize the risk of infection. Infection is such a significant risk that IV administration is often limited to a number of weeks, at most.
- the patient must wear an external pump connected to the percutaneous catheter if the therapy is intended to last longer than a few hours and the patient desires to be ambulatory.
- Subcutaneous drug delivery can be either partially implanted or totally implanted.
- Partially implanted systems rely on a percutaneous catheter or needle stick to deliver the medication, therefore, partially implanted systems have the same limitations as IV systems. Totally implanted systems have fewer maintenance requirements and are far less prone to infection than IV or partially implanted systems.
- the water-swellable agent in the water-swellable agent chamber expands in volume, it pushes on the movable piston, which correspondingly decreases the volume of the drug chamber and causes the drug to be released through a diffusion outlet at a substantially constant rate.
- a limitation of the osmotic pump disclosed in the above-identified patent is that its infusion rate cannot be adjusted once it is implanted. This is acceptable for medications that do not need rate adjustment, but often physicians desire to adjust the infusion rate based on the clinical status of the patient.
- One example of when a physician would want to increase the infusion rate is in the field of pain management.
- Osmotic pumps can be used to deliver medication to treat pain lasting over an extended period of time. Pain, however, often increases with time, and sometimes patients become tolerant to pain medications; therefore, more medication is needed to effectively treat the pain.
- the system disclosed in the above-identified patent does not allow a rate increase after implantation, so the physician must surgically remove the current implant and implant an additional pump to deliver the correct dosage. However, the prospect of yet another surgical procedure may cause many patients to forego the potential benefits of the larger dose and may also cause their physicians to advise against the initial procedure altogether.
- Another object of the present invention is to provide improved pumps.
- Another object of the present invention is to provide improved implantable osmotic pumps that conform to the patient's anatomy and that more closely match the topology of the implant site.
- a still further object is to provide novel implantable osmotic pumps for long term delivery of a pharmaceutical agent that do not rely upon a right-cylindrical pharmaceutical agent compartment and/or conventional cylindrical pistons.
- such improved pumps should enable the physician to increase the dose of pharmaceutical agent delivered to the patient without removing the pump from the implant site.
- an implantable osmotic pump for delivering a pharmaceutical agent to a patient, includes a catheter; an osmotic engine; a pharmaceutical agent compartment; a volume of pharmaceutical agent that includes Sufentanil within the pharmaceutical agent compartment, and a piston disposed within the compartment, the compartment being configured such that the osmotic engine causes the piston to travel within the compartment along an arcuate path and deliver the pharmaceutical agent through the catheter when the pump is implanted in the patient, wherein the pump is configured for: a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the catheter is placed intraventricularly; a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the catheter is placed intrathecally; a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the catheter is placed epidurally; a daily delivery rate of Sufentanil of up
- the compartment may be disposed at least partially around the osmotic engine.
- the osmotic engine may include a base, a cylindrical wall attached to the base and a free end opposite the base.
- the pump may further include a housing configured to enclose at least the osmotic engine and the compartment.
- the housing may include a first housing half and a second housing half that mates with the first housing half.
- Each of the first and second housing halves may define a saucer shape.
- Each of the first and the second housing halves may be substantially circular in shape.
- the first housing half may define a substantially circular opening.
- the pump may further include a membrane enclosure, the membrane enclosure being partially surrounded by the osmotic engine and may include an initial dose semipermeable membrane that may be configured to allow water from the patient to reach the osmotic engine when the pump is implanted.
- the pump may be configured to deliver an initial dose of the pharmaceutical agent to the patient at a selected initial infusion rate, the selected initial infusion rate being related to a thickness, a composition and/or a surface area of the initial dose semipermeable membrane.
- the initial dose semipermeable membrane may be fitted with an initial dose impermeable membrane that initially seals the initial dose semipermeable membrane.
- the pump may further include a volume of a saturated saline solution between the initial dose semipermeable membrane and the initial dose semipermeable membrane.
- the pump may further include a dose escalation assembly fitted in the membrane enclosure, the dose escalation assembly being adapted to selectively increase an amount of water from the patient that reaches the osmotic engine when the pump is implanted.
- the dose escalation assembly may include a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached.
- the dose escalation assembly may include: a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached, and a second impermeable membrane configured to enable water from the patient to reach the osmotic engine through a second fluid path only after being breached, the first path being distinct from the second path.
- the first and second impermeable membranes may be disposed in the membrane enclosure in a stacked configuration in which the first impermeable membrane must be breached before the second impermeable membrane can be breached.
- the first fluid path may include a first semipermeable membrane and the second fluid path may include a second semipermeable membrane that is distinct from the first semipermeable membrane.
- the pump may be configured to deliver a first dose of the pharmaceutical agent to the patient at a selected first infusion rate and a second dose of the pharmaceutical agent to the patient at a selected second infusion rate that may be greater than the first infusion rate, the selected first and second infusion rates being related to a thickness, a composition and/or a surface area of the first and second semipermeable membranes, respectively.
- the osmotic engine may include a hygroscopic salt, for example.
- the osmotic engine may include an absorbent polymer.
- the absorbent polymer may include a material selected from a group including poly(acrylic acid), potassium salt; poly(acrylic acid), sodium salt; poly(acrylic acid-co-acrylamide), potassium salt; poly(acrylic acid), sodium salt-graft-poly(ethylene oxide); poly (2-hydroxethyl methacrylate); poly(2-hydroxypropyl methacrylate) and poly(isobutylene-co-maleic acid) or derivatives thereof.
- the compartment may have a substantially constant inner diameter over a length thereof.
- the compartment may have a non-constant inner diameter over a length thereof.
- the catheter may include a radiopaque tip.
- the piston may include one of a sphere, an elastomeric cylinder and an elastomeric conical section.
- the piston may include at least one of stainless steel, a refractory metal, plastic, nylon and rubber.
- the sufentanil may be at a concentration up to about 500,000 ⁇ g/mL, for example.
- the dose escalation assembly may include: a first saturated saline solution between the first impermeable membrane and the first semipermeable membrane, and a second saturated saline solution between the second impermeable membrane and the second semipermeable membrane.
- the present invention is a method of delivering a pharmaceutical agent to a patient, comprising steps of: implanting a pump into the patient, the pump including a pump engine and a compartment adapted to store a pharmaceutical agent, and causing a piston to travel a distance within the compartment along an arcuate path and to deliver a dose of pharmaceutical agent out of the compartment.
- the implanting step may be carried such that the pharmaceutical agent is delivered one of intravascularly, subcutaneously, epidurally, intrathecally and intraventricularly.
- the pharmaceutical agent may include Sufentanil and the pump may be configured for: a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intraventricularly; a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intrathecally; a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered epidurally; a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered subcutaneously, and a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the implant
- Travel of the piston within the compartment may cause a delivery of a volume up to about 20 ⁇ L/day over a treatment period, for example.
- the method may further comprise the step of selectively increasing the dose in a stepwise manner over a treatment period without removing the pump from the patient.
- the pump engine may include an osmotic engine and the pump may include an initial dose semipermeable membrane initially exposed to the patient and at least one second semipermeable membrane initially not exposed to the patient and the increasing step may include a step of selectively exposing the at least one second semipermeable membrane to the patient.
- the pump the engine may include an osmotic engine in fluid communication with the piston and the causing step may include a step of increasing a volume of the osmotic engine.
- the present invention is a pump, comprising: a pump engine; a compartment adapted to store a fluid, the compartment being disposed at least partially around the pump engine, and a piston disposed within the compartment, the compartment and the engine being configured to cause the piston to travel within the compartment along an arcuate path and to force a volume of the fluid out of the pump.
- the pump engine may include an osmotic engine.
- the fluid may include a pharmaceutical agent.
- a catheter may be coupled to the compartment.
- the pump may be configured to be fully implantable in a body and pump engine and the compartment may be enclosed in a biocompatible pump housing.
- the pump may include a dose escalation assembly, the escalation assembly being configured to selectively increase the dose of fluid delivered.
- the dose escalation assembly may include means for increasing the dose delivered in a stepwise manner.
- the piston may include one of a sphere, an elastomeric cylinder and an elastomeric conical section.
- FIG. 1 is a perspective view of the osmotic pump according to an embodiment of the present invention.
- FIG. 2 is an exploded view of the osmotic pump according to an embodiment of the present invention, showing the major components thereof.
- FIG. 3 is a plan view of the osmotic pump according to an embodiment of the present invention in which the first half of the housing has been removed.
- FIG. 4 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines BB′.
- FIG. 5 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines AA′.
- FIG. 6 is a plan view of the second half of the osmotic pump housing, according to an embodiment of the present invention.
- FIG. 7 is a cross sectional view of the second half of the osmotic pump housing, taken along lines CC′.
- FIG. 8 is a perspective view of the first half of the osmotic pump housing according to an embodiment of the present invention.
- FIG. 9 is a plan view of the first half of the osmotic pump housing of FIG. 8.
- FIG. 10 is a cross-sectional view of the first half of the osmotic pump housing of FIG. 9, taken along lines DD′.
- FIG. 11 is a plan view of an embodiment of the membrane enclosure, according to an embodiment thereof.
- FIG. 12 is a perspective view of the membrane enclosure of FIG. 11, showing the semipermeable membrane wells in dashed lines.
- FIG. 13 is a plan view of an impermeable membrane can of an osmotic pump according to an embodiment of the present invention, showing the internal surface and through bore thereof in dashed lines.
- FIG. 14 shows a side view of the impermeable membrane can of FIG. 13.
- FIG. 15 is a plan view of the osmotic engine of the osmotic pump, according to an embodiment of the present invention.
- FIG. 16 is a side view of the osmotic engine of FIG. 15.
- FIG. 17 is a plan view of the coiled tube, according to an embodiment of the present invention.
- FIG. 18 is a cross-sectional view of the tube of FIG. 17, taken along line EE′.
- FIG. 19 is a cross-sectional view of the coiled tube of FIG. 17, taken along line FF′.
- FIG. 20 illustrates the tube coupled to a catheter, according to an embodiment of the present invention.
- FIG. 21 illustrates the distal tip of the catheter of FIG. 20, according to an embodiment of the present invention.
- FIG. 22 illustrates the proximal end of the catheter of FIG. 20, according to an embodiment of the present invention.
- FIG. 23 shows an embodiment of a piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 24 shows a further embodiment of a piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 25 shows a further embodiment of still another piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 26 shows a first step of a method by which the impermeable membrane of the first impermeable membrane may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 27 shows a second step of a method by which the impermeable membrane of the first impermeable membrane may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 28 shows a third step of a method by which the impermeable membrane of the first impermeable membrane can may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 29 shows a fourth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 30 shows a fifth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 31 shows a sixth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 32 is a plan view of another embodiment of the membrane enclosure, according to the present invention, showing the OFF feature of the present invention.
- FIG. 33 is a perspective view of the membrane enclosure of FIG. 32, showing the semipermeable membrane wells in dashed lines and the OFF switch feature of the present invention.
- FIG. 34 is an exploded view of another embodiment of an osmotic pump according to the present invention.
- FIG. 35 is an exploded view of a three-stage osmotic pump, according to another embodiment of the present invention.
- FIG. 36 a is a top view of a three stage osmotic pump according to the present invention, showing the internal structure thereof in dashed lines.
- FIG. 36 b is a reduced-size (relative to FIG. 36 a ) top view of a three stage osmotic pump, showing selected exemplary dimensions thereof.
- FIG. 37 is a cross-sectional view of a three stage osmotic pump according to the present invention, taken along cross-sectional line BB′ of FIG. 36.
- FIG. 38 is a cross-sectional view of a three stage osmotic pump according to the present invention, taken along cross-sectional line AA′ of FIG. 36.
- FIG. 39 is a cross-sectional view of the filter assembly 312 of FIG. 35.
- FIG. 40 is a front view of the filter assembly 312 of FIG. 35.
- FIG. 41 is a cross-sectional view of a piston, according to an embodiment of the present invention.
- FIG. 42 is a perspective view of a single stage osmotic pump according to another embodiment of the present invention.
- FIG. 43 is an exploded view of a single stage osmotic pump according to the present invention.
- FIG. 44 is a top view of a single stage osmotic pump according to the present invention, showing internal components thereof in dashed lines.
- FIG. 1 is a perspective view and FIG. 2 shows an exploded view of the pump 100 according to an embodiment of the present invention.
- the pump 100 includes a pump engine 108 and a substantially toroidal compartment around the engine 108 .
- the toroidal compartment is bounded by an inner radius 207 and an outer radius 208 and is adapted to contain a fluid, such as a pharmaceutical agent.
- the pharmaceutical agent compartment is tube-shaped and is defined by an inner lumen 110 of a tube 109 that may be coiled at least partially around the osmotic engine 108 .
- the tube 109 has a proximal end 184 and a distal end 186 .
- the tube 109 may include or be formed of, for example, polyimid.
- a piston 162 is disposed in the tube-shaped compartment 110 .
- the piston is adapted to travel (in the direction from the proximal end 184 to the distal end 186 of the tube 109 ) within the tube-shaped compartment 110 and to cause a volume of fluid to be forced out of the distal end 186 of the tube 109 .
- a catheter 102 may be coupled to the distal end 186 of the tube 109 , to enable the fluid forced out the distal end 186 of the tube 109 to be delivered to the intended delivery site within the patient.
- the pump engine 108 includes an osmotic engine.
- the pump 100 may further include a pump housing 101 that is configured to enclose (at least) the pump engine 108 and the tube 109 .
- the pump housing 101 may include a first housing half 106 and a mating second housing half 104 .
- the first and second pump housing halves 106 , 104 mate to one another like a clamshell, in a fluid-tight fashion.
- the first and second housing halves 106 , 104 may each have a generally circular outline (as may the entire pump 100 ) and have a generally define a saucer shape.
- the first housing half 106 may further define an opening 140 , which may be circular in shape.
- the present invention will now be described in terms of an implantable osmotic pump for delivering a pharmaceutical agent to a patient, although the present invention is not so limited.
- the pump and/or the catheter 102 may be implanted intravascularly, subcutaneously, epidurally, intrathecally and/or intraventricularly, for example.
- the pump engine 108 (referred to hereafter as osmotic engine 108 , although the present invention is not limited to osmotic-type pump engines) may be shaped like hollow, open-ended right cylinder.
- the osmotic engine 108 is hygroscopic and may include a salt block or a “salt wafer” and/or may include an absorbent polymer, such as poly(acrylic acid), potassium salt; poly(acrylic acid), sodium salt; poly(acrylic acid-co-acrylamide), potassium salt; poly(acrylic acid), sodium salt-graft-poly(ethylene oxide); poly (2-hydroxethyl methacrylate) and/or poly(2-hydroxypropyl methacrylate) and poly(isobutylene-co-maleic acid). Suitable absorbent polymers are available from Aldrich, Inc. of Milwaukee, Wis., for example.
- the osmotic engine 108 may include a base that may be disposed in a correspondingly shaped depression defined in the second housing half 104 and a cylindrical wall attached to the base.
- the pump 100 may include a generally cylindrical-shaped membrane enclosure 112 .
- the membrane enclosure 112 may be fitted within and partially surrounded by the pump engine 108 .
- the membrane enclosure 112 is dimensioned to closely fit the opening 140 defined in the first housing half 106 .
- the membrane enclosure 112 may include an initial dose semipermeable membrane (formed of or including cellulose acetate, for example), as shown in FIG. 5, to create a fluid path for water through the initial water access port 130 defined in the membrane enclosure 112 to the osmotic engine 108 .
- the initial water access port 130 may be spanned by a thin impermeable membrane 182 , thereby defining an interstitial space between the initial dose semipermeable membrane and the impermeable membrane.
- This interstitial space may be filled with a saturated saline solution, to keep the initial dose semipermeable membrane fully hydrated prior to implantation of the pump 100 in a patient (not shown).
- the physician may breach the impermeable membrane 182 spanning the initial water access port 130 to allow water from the patient to enter the initial dose semipermeable membrane well 150 (see FIG. 12) and migrate across the initial dose semipermeable membrane 134 (see FIG. 5) to reach the osmotic engine 108 .
- the initial water access port 130 , the thin impermeable membrane 182 and the saturated saline solution effectively form a pump ON switch.
- the pump 100 does not deliver any pharmaceutical agent to the patient. It is only after breaching the thin impermeable membrane 182 that the pump becomes effective to initiate delivery of the contained pharmaceutical agent to the patient.
- the saturated saline solution between the impermeable membrane 182 and the underlying initial dose semipermeable membrane 150 insures that the onset of delivery of the pharmaceutical agent is not delayed by the time required for the initial dose semipermeable membrane 150 to hydrate.
- the membrane enclosure 112 may also define a primary water access port 132 that may be (but need not be) concentric with the circumference of the membrane enclosure 112 .
- a dose escalation assembly may fit within the primary water access port 132 .
- the dose escalation assembly is adapted to selectively increase the amount of water from implantation site within the patient that reaches the osmotic engine 108 .
- the dose escalation assembly may include one or more impermeable membrane cans fitted within the primary water access port 132 of the membrane enclosure 112 .
- the dose escalation includes a first impermeable membrane can 114 stacked upon a second impermeable membrane can 116 whose structure and function is described hereunder.
- FIG. 3 is a plan view of the osmotic pump according to an embodiment of the present invention in which the first half of the housing has been removed
- FIG. 4 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines BB′ of FIG. 3
- FIG. 5 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines AA′.
- FIG. 3 shows the tube 109 coiled around the osmotic engine 108 from the proximal end 184 to the distal end thereof, shown at 186 .
- the distal end 186 of the coiled tube 109 may be fitted with a catheter ID tube 118 that facilitates the coupling of the catheter 102 to the distal end 186 of the tube 109 .
- the initial water access port 130 may lead to an initial dose semipermeable membrane 134 within the membrane enclosure 112 .
- the membrane enclosure 112 is configured to enable water from the patient to flow into the initial water access port 130 , to migrate across the initial dose semipermeable membrane 134 to reach the osmotic engine 108 .
- the engine 108 swells in volume and increases the osmotic pressure differential across the initial dose semipermeable membrane 134 and pushes the piston 160 within the tube-shaped compartment defined by the tube 109 toward the distal end 186 thereof, as the expansion of the osmotic engine 108 is constrained to within the tube-shaped compartment 110 .
- the piston 160 displaces a volume of pharmaceutical agent within the tube-shaped compartment 110 , which displaced volume of pharmaceutical agent is delivered out of the distal end 186 of the tube 109 .
- the pharmaceutical agent is delivered at a selected initial infusion rate that is related to the thickness, composition and surface area of the initial dose semipermeable membrane 134 .
- the pharmaceutical agent within the tube-shaped compartment is quickly delivered to the patient at the selected initial infusion rate. If the initial dose semipermeable membrane 134 is not pre-hydrated, the delivery of the pharmaceutical agent may be delayed until the membrane 134 becomes at least partially hydrated from water from the patient implant site. Until at least the first impermeable membrane cans 114 is breached, the only water that reaches the osmotic engine 108 enters the pump 100 through the initial water access port 130 to cross the initial dose semipermeable membrane 134 .
- the membrane assembly 112 includes a first semipermeable membrane 120 and a second semipermeable membrane 124 .
- the diameter of the semipermeable membranes 120 , 124 is directly proportional to the flow rate of the pump of the present invention.
- the first semipermeable membrane 120 may be (but need not be) vertically offset from the second semipermeable membrane 124 in the membrane enclosure 112 .
- FIGS. 13 and 14 of which FIG. 13 is a plan view of an impermeable membrane can 114 , 116 and of which FIG. 14 is a side view of the impermeable membrane can 114 , 116 of FIG. 13.
- the cans 114 , 116 include a cylindrical sidewall 154 and a through bore defined therein.
- the sidewall of the first impermeable membrane can 114 defines a first through bore 122 and the sidewall of the second impermeable membrane can 116 defines a second through bore 126 .
- An impermeable membrane 152 (shown in FIGS. 13 and 14 in its intact state) spans one of the free ends of each of the cans 114 , 116 .
- the impermeable membranes 152 are impermeable at least to water from the patient implant site and are configured to be easily breached by the physician, as is detailed below.
- the impermeable membranes 152 may include or be formed of most any water impermeable material that is biologically inert, such as titanium and/or stainless steel, coated platinum or platinum-iridium for radiopacity, for example.
- the impermeable membranes 152 of the first and second cans 114 , 116 may be surface ground to a thickness of about 1 or 2 thousandths of an inch, for example.
- the impermeable membranes 152 may alternatively include polyethylene, PET, PETG or PETE, for example.
- the impermeable membranes 152 are radiopaque, so as to be visible under fluoroscopy, once the pump 100 is implanted.
- a layer of radiopaque material may be sputtered or otherwise deposited on the impermeable membranes 152 , to render them visible under fluoroscopy.
- the impermeable membranes 110 are adapted to be breached by the physician or clinician, using a dose escalation pen (or a lancet or stylet as shown in FIGS. 26-31), or some other functionally similar device.
- the impermeable membranes 152 of the first and second impermeable membrane cans 114 , 116 initially seal the first and second semipermeable membranes 120 , 124 to prevent any water originating from the patient's implant site from crossing the semipermeable membranes 120 , 124 until the impermeable membrane(s) 152 is breached, as shown at 176 in FIGS. 28-31.
- the first and second impermeable membrane cans 114 , 116 are stacked within the membrane enclosure 112 such that the respective through bores 122 , 126 thereof are aligned with the first and second semipermeable membranes 120 , 122 , respectively.
- the first through bore 122 defined in the first impermeable membrane can 114 is aligned with the first semipermeable membrane 120
- the second through bore 126 defined in the second impermeable membrane can 116 is aligned with the second semipermeable membrane 124 .
- the impermeable membrane 152 of the first impermeable membrane can 114 is disposed adjacent the primary water access port 132
- the second impermeable can 116 is disposed under the first impermeable membrane can 114 and oriented such that the impermeable membrane thereof is immediately adjacent the first impermeable membrane can 114 .
- the present figures show the pump 100 of the present invention equipped with two impermeable membrane cans 114 , 116 , the present invention is not limited thereto, as a single or a greater number of impermeable membrane cans may be used along with a corresponding number of semipermeable membranes.
- FIG. 6 is a plan view of the second half 104 of the osmotic pump housing 101 , according to an embodiment of the present invention and FIG. 7 is a cross sectional view thereof, taken along lines CC′.
- the second half 104 of the pump housing 101 may have a generally saucer-like shape.
- the second half 104 of the housing 101 may have a generally circular outline and may define a bulge 136 therein to accommodate a portion of the osmotic engine 108 therein.
- the rim of the second half 104 (See FIG. 10) of the pump housing 101 also defines an indentation 138 adapted to mate with a corresponding feature defined by the rim of the first half 106 of the pump housing 101 .
- FIG. 10 is a plan view of the second half 104 of the osmotic pump housing 101 , according to an embodiment of the present invention and FIG. 7 is a cross sectional view thereof, taken along lines CC′.
- the second half 104 of the pump housing 101 may have
- FIG. 8 is a perspective view of the first half 106 of the osmotic pump housing 101 according to an embodiment of the present invention
- FIG. 9 is a plan view
- FIG. 10 is a cross-sectional view thereof, taken along lines DD′.
- an opening 140 is defined in the also generally saucer-shaped first half 106 of the osmotic pump housing 101 .
- the opening 140 may be centered in the housing half 106 and concentric with the generally circular outline thereof, as shown in FIG. 9.
- the opening 140 is preferably dimensioned so as to closely fit the membrane enclosure 112 .
- the first half 106 of the pump housing 101 may define a bulge 144 that increases the interior volume of the pump 100 when the first and second housing halves 106 , 104 are mated to one another.
- FIG. 11 is a plan view of an embodiment of the membrane housing 112 , according to an embodiment thereof, whereas FIG. 12 is a perspective view of the membrane housing of FIG. 11, showing the semipermeable membrane wells in dashed lines.
- the membrane enclosure 112 may be shaped as a cylinder dimensioned to fit within the osmotic engine 108 and the opening 140 in the first housing half 106 .
- the primary water access port 132 may be a bore partially through the membrane enclosure 112 .
- the bore defined within the membrane enclosure 112 should not run the entire length of the membrane enclosure 112 .
- the only water paths from the implant site to the osmotic engine should be through the initial dose semipermeable membrane well 150 , through the first semipermeable membrane well 146 and/or through the second semipermeable membrane well 150 .
- the combination of the initial water access port 130 and the initial dose semipermeable well 150 runs the entire length of the membrane enclosure 112 , as also shown in FIG. 5. Indeed, once the pump 100 is implanted in the patient and any impermeable membrane that may span the initial water access port 130 is breached, a water path to the osmotic engine 108 may be defined straight through the membrane enclosure 112 , as the water from the implant site migrates across the initial dose semipermeable membrane (shown at 134 in FIG. 5) fitted within the initial dose semipermeable membrane well 150 .
- First and second semipermeable membranes 120 , 124 are fitted within the first and second semipermeable membrane wells 146 , 148 , respectively.
- water from the implant site may enter the primary access port 132 and travel through the first through bore 122 of the first impermeable membrane can 114 . From there, the water may travel through a first passageway 188 , defined between primary water access port 132 and first semipermeable membrane well 146 .
- the water After crossing the first semipermeable membrane 120 disposed in the well 146 , the water reaches the osmotic engine 108 .
- This first water path is shown at 178 in FIGS. 28, 29 and 31 .
- the engine 108 swells in volume due to the osmotic pressure differential across the first semipermeable membrane 120 and pushes the piston 160 , 162 within the tube-shaped compartment 110 defined within the tube 109 toward the distal end 186 thereof.
- the piston 160 , 162 displaces a volume of pharmaceutical agent within the tube-shaped compartment 110 , which displaced volume of pharmaceutical agent is delivered out of the distal end 186 of the tube 109 .
- the pharmaceutical agent is delivered at a selected first infusion rate that is related to the thickness, composition and surface area of the first semipermeable membrane 120 and that of the initial dose semipermeable membrane 134 .
- the engine 108 swells in volume due to the osmotic pressure differential across the second semipermeable membrane 124 and pushes the piston 160 , 162 within the tube-shaped compartment 110 defined by the tube 109 toward the distal end 186 thereof.
- the piston 160 displaces a volume of pharmaceutical agent within the tube-shaped compartment 110 , which displaced volume of pharmaceutical agent is delivered out of the distal end 186 of the tube 109 .
- the pharmaceutical agent is delivered at a selected second infusion rate that is related to the thickness, composition and surface area of the second semipermeable membrane 124 , the thickness, composition and surface area of the first semipermeable membrane 120 and the thickness, composition and surface area of the initial dose semipermeable membrane 134 .
- the infusion rate of the pump 100 is related to which of the semipermeable membranes 134 , 120 and/or 124 are currently exposed to the patient. If only the initial dose semipermeable membrane 134 is exposed to the patient, the infusion rate may be related only to the characteristics of the initial dose semipermeable membrane 134 .
- the pump infusion rate may be related to the characteristics of both the initial dose and first semipermeable membranes 134 , 120 .
- the total infusion rate of the pump 100 of the present invention in the state wherein both the initial dose semipermeable membrane 134 and the first semipermeable membrane 120 are breached may be approximated as the sum of the individual infusion rates contributed by each of the semipermeable membranes 134 and 120 .
- the pump infusion rate may be related to the characteristics of the initial dose, the first and the second semipermeable membranes 134 , 120 and 124 .
- the total infusion rate of the pump of the present invention in the state wherein the impermeable membranes 134 , 120 and 124 are breached may be approximated as the sum of the individual infusion rates contributed by each of the semipermeable membranes 134 , 120 and 124 .
- FIG. 17 is a plan view of the coiled tube 109 , according to an embodiment of the present invention
- FIG. 18 is a cross-sectional view of the tube 109 of FIG. 17, taken along line EE′
- FIG. 19 is a cross-sectional view thereof, taken along line FF′.
- the piston 160 may initially (upon implantation) be disposed within the tube-shaped compartment 110 near the proximal end 184 of the tube 109 . As the osmotic engine expands in volume, the only available volume for such expansion is within the tube-shaped compartment 110 .
- the expansion of the osmotic engine 108 forces the piston 160 to travel through the coiled tube 109 in the direction of arrow 166 , which causes a volume of pharmaceutical agent to be delivered to the patient out of the distal end 186 of the tube 109 .
- a catheter ID (inner diameter) tube 118 may be fitted onto the distal end 186 of the tube 109 , which facilitates coupling the catheter 102 thereto.
- the tube 109 may be coiled a number of times around the membrane enclosure 112 . In the embodiment shown in FIGS. 17-19, the tube 109 is coiled four times around the membrane enclosure 112 (not shown in FIGS. 17-19), although a lesser or greater number of coils may readily be implemented.
- FIG. 20 illustrates the tube 109 coupled to a catheter 102 , according to an embodiment of the present invention.
- FIG. 21 illustrates the distal tip of the catheter of FIG. 20, according to an embodiment of the present invention and
- FIG. 22 illustrates the manner in which the catheter may couple to the catheter ID tube 118 .
- the outline of the pump housing 101 is shown for reference purposes.
- the catheter 102 is used to deliver the pharmaceutical agent from the catheter ID tube 118 to the target area within the patient's body.
- the catheter 102 may be visible under fluoroscopy over its length, thereby enabling the physician to trim the catheter to the desired length.
- the catheter 102 may include distal radiopaque markers, for example. As shown in FIG.
- the distal tip 158 of the catheter 102 may included a rounded, atraumatic tip.
- a plurality of pharmaceutical agent openings 158 may be defined through the catheter wall, from the internal lumen thereof to the patient.
- the catheter ID may be fitted over the catheter ID tube 118 using a friction fit and/or suitable biocompatible adhesive(s), for example.
- Any suitable radio opaque material may be used to render all or a portion or selected portions of the catheter 102 radio opaque.
- the catheter 102 may be formed of silicone or polyurethane and may be doped with barium sulfate, for example.
- the length of the catheter 102 may be most any therapeutically effective length.
- the catheter 102 may be about 5 cm to about 100 cm in length. More preferably, the catheter 102 may be about 10 cm to about 30 cm in length. More preferably still, the catheter 012 may be about 15 cm to about 25 cm in length. For example, the catheter 102 may be about 20 cm in length.
- the internal diameter (ID) of the infusion lumen of the catheter 102 may be selected within the range of about 0.001 inches to about 0.010 inches.
- the walls of the catheter 102 may be about 0.001 inches to about 0.006 inches in thickness.
- the outer diameter (OD) of the catheter 102 may be selected between about 0.024 inches and about 0.066 inches in thickness, for example.
- FIGS. 23-25 are cross sections of the tube 109 , showing various designs for the piston within the tube shaped compartment 110 .
- the piston of the osmotic pump 100 of the present invention may be spherical, as shown at 160 , cylindrical as shown at 162 or may approximate a conical section as shown at 163 , although other shapes are possible.
- a spherical shape minimizes the contact points of the piston 160 with the tube-shaped compartment 110 , thereby enabling the piston 160 to travel through the compartment 110 , even as the radius of curvature thereof changes form the proximal end 184 to the distal end of the tube 109 .
- Reference 170 represents slurry from the osmotic engine 108 .
- reference 170 may be considered to be an extension of the osmotic engine 108 , as it swells with water from the patient implant site through the semipermeable membranes 134 , 120 and/or 124 .
- the osmotic engine 108 swells in volume, it exerts a force 168 on the piston 160 , 162 or 163 , forcing it to travel within the tube-shaped compartment 110 in the direction of arrow 166 .
- the piston 160 , 162 , 163 displaces a corresponding volume of pharmaceutical agent 164 .
- the piston 160 , 162 , 163 may include stainless steel, nylon or an elastomer, for example.
- the piston 162 may be formed of an elastomeric substance, such as butyl rubber, for example. Such a cylindrical piston 162 may then deform to match the radius of curvature of the tube-shaped compartment 110 .
- the inner diameter of the tube 109 (that is, the diameter of the tube-shaped compartment 110 ) may be constant over the length of the tube 109 or may become larger or smaller over its length.
- the piston 163 may assume a truncated conical shape, in which a proximal end thereof is smaller than a distal end thereof (or vice-versa), to match the change in inner diameter of the tube-shaped compartment 110 .
- the coiled tube 109 may be encased in a hard substance, such as epoxy, for example.
- FIG. 26-28 shows steps of a method by which the impermeable membrane 152 of the first impermeable membrane can 114 may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 29-31 shows further steps of the method by which the impermeable membrane 152 of the second impermeable membrane can 116 may be breached so as to further escalate the dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention. While any device may be used to breach the impermeable membranes 152 , a dose escalation pen or stylet 172 similar to that shown in FIGS. 26-31 may be advantageously used.
- An actuator 192 such as a thumb actuated wheel, may be coupled to a pointed extendible portion 200 of the pen 172 . Actuating the actuator 192 may cause the pointed and extendible portion 200 to extend in length from a first length 202 shown in FIGS. 26-28, to a second length 204 shown in FIGS. 29-31.
- the patient may require a greater dose of pharmaceutical agent than provided by the initial dose, which initial dose is driven by the osmotic engine 108 swelling in response to water entering the initial water access port 132 .
- the physician may, according to the present invention, use a dose escalation pen or stylet to increase the effusion rate of the pharmaceutical agent from the pump 100 in a simple office or outpatient procedure.
- the impermeable membranes 152 prevent any water from the patient implant site from reaching the first and second semipermeable membranes 120 , 124 .
- the physician wishes to increase the dose of pharmaceutical agent delivered to the patient, he or she may use the dose escalation pen 172 in a configuration wherein the pointed extendible portion 200 thereof is extended only to the first length 202 .
- the physician may breach the impermeable membrane 152 of the first impermeable membrane can 114 , as shown at FIG. 27.
- the first length 202 of the extendible portion 200 is selected so as to breach only the impermeable membrane 152 of the first can 114 , and not that of the second can 116 .
- the outer diameter of the extendible portion 200 is slightly smaller than the outer diameter of the cans 114 , 116 , to enable the dose escalation pen 172 to create a wide opening when breaching the impermeable membranes 152 .
- the handle portion 206 of the pen 172 should have a diameter that is slightly larger than the outer diameter of the cans 114 , 116 , to limit the travel of the extendible portion 200 within the cans 114 , 116 .
- a first water path 178 is created, from the patient implant site through the first impermeable membrane can 114 , through the first through bore 122 thereof, across the first semipermeable membrane 120 to the osmotic engine 108 .
- water may now reach the osmotic engine 108 through the initial water access port 132 and through the first impermeable membrane can 114 .
- the physician may actuate the actuator 192 to change the length of the extendible portion 200 to the second length 204 , which second length 204 is sufficient to penetrate the first can 114 and breach the impermeable membrane 152 of the second impermeable membrane can 116 , as shown at 177 FIG. 31.
- the dose escalation pen 172 is retracted as shown at FIG. 31, a second water path 180 is created.
- the second water path 180 runs from the patient implant site through the first impermeable membrane can 114 , through the breached impermeable membrane 152 of the second can 116 , through the second through bore 126 of the second can 116 , across the second semipermeable membrane 124 to the osmotic engine 108 .
- water may now reach the osmotic engine 108 through the initial water access port 132 , through the first impermeable membrane can 114 as well as through the second impermeable membrane can 116 .
- the tube-shaped compartment 110 of the pump 100 may be pre-loaded with one or more pharmaceutical agents 30 .
- the pharmaceutical agent may be therapeutically effective for one or more of the following therapies: pain therapy, hormone therapy, gene therapy, angiogenic therapy, anti-tumor therapy, chemotherapy, allergy therapy, hypertension therapy, antibiotic therapy, bronchodilation therapy, asthmatic therapy, arrhythmia therapy, nootropic therapy, cytostatic and metastasis inhibition therapy, migraine therapy, gastrointestinal therapy and/or other pharmaceutical therapies.
- the pharmaceutical agent may include an opioid, a morphine-like agonist, a partial agonist, an agonist-antagonist and/or an alpha 2-adrenoreceptor agonist.
- the pharmaceutical agent may include morphine, hydromorphone, levorphanol, methadone, fentanyl, sufentanil, buprenorphine, pentazocine and/or butorphanol, for example.
- the pharmaceutical agent may, for example, include an analgesic agent such as Dihydrocodeine, Hydromorphone, Morphine, Diamorphine, Levorphanol, Butorphanol, Alfentanil, Pentazocine, Buprenorphine, Nefopam, Dextropropoxyphene, Flupirtine, Tramadol, Oxycodone, Metamizol, Propyphenazone, Phenazone, Nifenazone, Paracetamol, Phenylbutazone, Oxyphenbutazone, Mofebutazone, Acetyl Salicylic Acid, Diflunisal, Flurbiprofen, Ibuprofen, Diclofenac, Ketoprofen, Indomethacin, Naproxen, Meptazinol, Methadone, Pethidine, Hydrocodone, Meloxicam, Fenbufen, Mefenamic Acid, Piroxicam, Tenoxicam, Azapropazone, Codein, Bupivacaine, Ke
- the pharmaceutical agent may also include analgesic that is an alpha-2 adrenergetic agonist such as Clonidine, Tizadine, ST-91, Medetomidine, Dexmedetomidine and/or related alpha-2 adrenergetic agonists.
- the analgesic may also include an N-methyl-D-aspartate (NMDA) receptor agonist including Dexmethorphan, Ifenprodil, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801), and/or related NMDA agonists.
- NMDA N-methyl-D-aspartate
- the analgesic may also include a somatostatin analog selected including Octreotide, Sandostatin, Vapreotide, Lanreotide, and/or related Somatostatin analogs, for example.
- the pharmaceutical agent may include a non-opioid analgesic such as Ketorolac, super oxide dismutase, baclofen, calcitonin, serotonin, vasoactive intestinal polypeptide, bombesin, omega-conopeptides, and/or related non-opioid analgesics, for example.
- the pharmaceutical agent in the compartment 310 may be dissolved in an aqueous solution.
- a preferred pharmaceutical agent is Sufentanil.
- the pharmaceutical agent is (or includes) Sufentanil that is dissolved in an aqueous medium
- the solubility of the Sufentanil within the aqueous solution increases with increasing acidity of the medium.
- the pumps according to the present invention may be configured to deliver Sufentanil at up to about 1500 ⁇ g/day, at a concentration of up to about 500,000 ⁇ g/ml, when the Sufentanil is dissolved in an acidic aqueous medium.
- a pump according to the present invention may include a pharmaceutical agent compartment 310 having a volume of 500 ⁇ l (microliters).
- a compartment 310 of this volume may contain 500 ⁇ l of pharmaceutical agent solution, the solution including 250,000 ⁇ g of Sufentanil dissolved in an acidic aqueous medium. Therefore, about 1500 ⁇ g/day of such pharmaceutical agent solution may be delivered to the patient over a treatment period spanning about 167 days. Implanted into a patient, such a pump would deliver about 3 ⁇ l of pharmaceutical agent solution to the patient per day, each such 3 ⁇ l of pharmaceutical agent solution containing about 1500 ⁇ l of Sufentanil.
- the pharmaceutical agent may also include an anti-allergic agent including Pheniramine, Dimethindene, Terfenadine, Astemizole, Tritoqualine, Loratadine, Doxylamine, Mequitazine, Dexchlorpheniramine, Triprolidine and/or Oxatomide, for example.
- an anti-allergic agent including Pheniramine, Dimethindene, Terfenadine, Astemizole, Tritoqualine, Loratadine, Doxylamine, Mequitazine, Dexchlorpheniramine, Triprolidine and/or Oxatomide, for example.
- the pharmaceutical agent may include one or more anti-hypertensive agents, such as Clonidine, Moxonidine, Methyldopa, Doxazosin, Prazosin, Urapidil, Terazosin, Minoxidil, Dihydralalzin, Deserpidine, Acebutalol, Alprenolol, Atenolol, Metoprolol, Bupranolol, Penbutolol, Propranolol, Esmolol, Bisoprolol, Ciliprolol, Sotalol, Metipranolol, Nadolol, Oxprenolol, Nifedipine, Nicardipine, Verapamil, Diltiazim, Felodipine, Nimodipine, Flunarizine, Quinapril, Lisinopril, Captopril, Ramipril, Fosinoprol and/or Enalapril, for example.
- the pharmaceutical agent may include an antibiotic agent such as Democlocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline, Sulfametopyrazine, Ofloaxcin, Ciproflaxacin, Aerosoxacin, Amoxycillin, Ampicillin, Becampicillin, Piperacillin, Pivampicillin, Cloxacillin, Penicillin V, Flucloxacillin, Erythromycin, Metronidazole, Clindamycin, Trimethoprim, Neomycin, Cefaclor, Cefadroxil, Cefixime, Cefpodoxime, Cefuroxine, Cephalexin and/or Cefradine, for example.
- an antibiotic agent such as Democlocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline, Sulfametopyrazine, Ofloaxcin, Ciproflaxacin, Aero
- Bronchodialotors and anti-asthmatic agents may also be pre-loaded into the tube-shaped compartment 110 , including Pirbuterol, Orciprenaline, Terbutaline, Fenoterol, Clenbuterol, Salbutamol, Procaterol, Theophylline, Cholintheophyllinate, Theophylline-ethylenediamine and/or Ketofen, for example.
- Anti-arrhythmic agents may also be pre-loaded into the pump 100 , including Viquidil, Procainamide, Mexiletine, Tocainide, Propafenone and/or Ipratropium, for example.
- the pharmaceutical agent may alternatively include a centrally acting substance such as Amantadine, Levodopa, Biperiden, Benzotropine, Bromocriptine, Procyclidine, Moclobemide, Tranylcypromine, Tranylpromide, Clomipramine, Maprotiline, Doxepin, Opipramol, Amitriptyline, Desipramine, Imipramine, Fluroxamin, Fluoxetin, Paroxetine, Trazodone, Viloxazine, Fluphenazine, Perphenazine, Promethazine, Thioridazine, Triflupromazine, Prothipendyl, thiothixene, Chlorprothixene, Haloperidol, Pipamperone, Pimozide, Sulpiride, Fenethylline, Methylphenildate, Trifluoperazine, Oxazepam, Lorazepam, Bromoazepam, Alprazol
- Cytostatics and metastasis inhibitors may also be pre-loaded within the pump 100 of the present invention, including Melfalan, Cyclophosphamide, Trofosfamide, Chlorambucil, Busulfan, Prednimustine, Fluororacil, Methotrexate, Mercaptopurine, Thioguanin, Hydroxycarbamide, Altretamine and/or Procarbazine, for example.
- anti-migrane agents such as Lisuride, Methysergide, Dihydroergotamine, Ergotamine and/or Pizotifen
- gastrointestinal agents such as Cimetidine, Famotidine, Ranitidine, Roxatidine, Pirenzipine, Omeprazole, Misoprostol, Proglumide, Cisapride, Bromopride and/or Metoclopramide.
- the present invention is also a kit, including an implantable osmotic pump 100 , a catheter 102 configured to attach to the pump 100 and/or dose escalation pen(s) 172 configured to breach the impermeable membranes 152 of the first and/or second cans 114 , 116 .
- FIGS. 32 and 33 are plan and perspective views, respectively, of a membrane enclosure 112 , according to embodiment of the present invention that addresses this need.
- the membrane enclosure 112 of FIGS. 32 and 33 is identical to the membrane enclosure of FIGS. 11 and 12, but for the presence of the structure referenced at 209 .
- Reference 209 denotes an OFF switch that is configured to enable the physician to nullify or substantially nullify the osmotic pressure differential across any and all semipermeable membranes such as shown at 120 or 124 .
- the OFF switch 209 includes an OFF switch impermeable membrane 210 and an OFF switch impermeable lumen 211 .
- fluid from the patient's implant site flows into the OFF switch lumen 211 , bypasses the semipermeable membranes, and flows directly to the osmotic engine 108 .
- any existing osmotic pressure that may have developed across such semipermeable membranes is reduced to zero or substantially zero, which correspondingly reduces the pump's driving force and reduces the delivery rate of the pharmaceutical agent to zero or about zero.
- the pump may then be explanted from the patient at will or may simply be left in place.
- FIG. 34 is an exploded view of another embodiment of an osmotic pump according to the present invention.
- FIG. 34 is similar to FIG. 1, but for the osmotic engine 108 . Accordingly, the description of the structures in FIG. 1 that are identical to structures in FIG. 34 is incorporated herein by reference.
- the osmotic engine is disposed within the tube 109 , at or near the proximal end 184 thereof.
- the tube in this case, is preferably rigid and may be formed of, for example, stainless steel or titanium. In this manner, the expansion of the osmotic engine 108 may be entirely constrained within the tube 109 , thereby pushing the piston 162 within the tube 109 toward the proximal end 186 thereof.
- FIG. 35 is an exploded view of a three-stage osmotic pump 300 , according to another embodiment of the present invention.
- FIG. 36 is a top view of a three stage osmotic pump according to the present invention, showing the internal structure thereof in dashed lines.
- FIGS. 37 and 38 are cross-sectional views of a three stage osmotic pump according to the present invention, taken along cross-sectional line BB′ and AA′ of FIG. 36.
- FIGS. 35-38 collectively, the constituent elements of the pump 300 that are similar to corresponding elements in FIG. 2 are identified by the same reference numerals and the detailed description thereof is omitted here.
- the osmotic pump 300 includes a substantially saucer-shaped housing that includes a first housing half 302 and a second housing half 304 that mates with the first housing half 302 .
- the osmotic pump 300 of FIG. 35 does not include a tube, such as tube 109 .
- the first and second halves 302 , 304 of the pump housing together define a tube-shaped and fluid-tight compartment 310 that is adapted to enclose a pharmaceutical agent.
- the compartment 310 is substantially toroidal in shape, in that it resembles a tube that curves around the osmotic engine 306 , following the outer curvature of the pump housing throughout most of its length.
- the tube-shaped compartment 310 defines a first end 330 that is in fluid communication with the osmotic engine 306 through a passageway 332 and a second end 334 adjacent the compartment outlet 314 that is formed when the first and second halves 302 , 304 of the housing are joined together.
- the pump 300 includes a piston 316 that is configured and adapted to travel within the compartment 310 in response to the force exerted thereon by the osmotic engine 306 .
- the piston 316 As the piston 316 travels within the compartment 310 , it displaces a volume of pharmaceutical agent.
- the piston 316 when the pump 300 is first implanted, is located adjacent the first end 330 of the compartment 310 and thereafter travels from the first end 330 toward the second end 334 , displacing a volume of pharmaceutical agent as it travels.
- FIG. 41 shows a cross-section of an exemplary embodiment of a piston 316 . As shown therein, the piston 316 may define a leading end 322 and a trailing end 324 .
- the outer surface of the piston may define one or more throughs 328 and ridges 326 , thereby further facilitating the travel of the piston 316 through the compartment 310 .
- the pump 300 when configured for systemic delivery of a pharmaceutical agent (as is the case wherein the pump is implanted subcutaneously, for example), may include a filter assembly 312 .
- the filter assembly 312 is configured to fit within the compartment outlet 314 , so as to maintain the substantially circular footprint of the pump 300 , as shown most clearly in FIG. 36.
- the structure of the filter assembly 312 is further described below, with reference to FIGS. 39 and 40.
- the filter assembly 312 filters the flow of the pharmaceutical agent from the pump 300 to the implant site within the patient or to the aqueous environment in which the pump is deployed.
- the filter assembly 312 prevents the passage of crystallized pharmaceutical agents to the patient. Crystallized pharmaceutical agents present a danger to the patient, in that the crystallized portion may contain an excess amount of agent and may cause an overdose.
- the volume of pharmaceutical agent that may be contained therein may be estimated by:
- n is about 270°, as the portion of the compartment 310 that is free to enclose pharmaceutical agent (i.e., from the leading edge 317 of the piston 316 to the proximal edge 313 of the filter assembly 312 ) spans about 3 ⁇ 4 of the circumference of the pump 300 .
- the pump 300 may also include a ring 308 .
- the ring 308 is preferably formed of the same material as the first and second housing halves 302 , 304 such as stainless steel, titanium or alloys thereof, for example.
- the piston 316 may be placed adjacent the first end 330 of the compartment 310 and the osmotic engine 306 may be centered between the first and second housing halves 302 , 304 .
- the first and second housing halves 302 , 304 may then be welded together, along the circumferential seam thereof.
- the first and second impermeable membrane cans 114 , 116 may then be inserted into the membrane enclosure, properly aligned therein and secured thereto.
- the ring 308 may then be inserted into the central opening formed by the first and second housing halves 302 , 304 and the semipermeable membrane enclosure 112 , complete with the first and second impermeable cans 114 , 116 may then be dropped into the central opening of the ring 308 , taking care to align the first through bore 124 with the first semipermeable membrane well 146 and the second through bore 124 with the second semipermeable membrane well 148 .
- the enclosure 112 may then be welded to the ring 308 and the ring 308 may be welded to the first half 302 of the pump housing (not necessarily in that order).
- the compartment 310 may then be filled with pharmaceutical agent (not shown in FIG.
- the filter assembly 312 may thereafter be fitted within the compartment outlet 314 and secured therein.
- the initial dose semipermeable membrane fitted within the initial dose semipermeable membrane well 336 is not shown in FIGS. 35-38, nor is the first semipermeable membrane fitted within the first semipermeable membrane well 146 or the second semipermeable membrane fitted within the second semipermeable membrane well 148 .
- the membrane enclosure 112 may also incorporate the OFF switch features shown in FIGS. 32 and 33.
- the pump 300 is adapted to deliver a pharmaceutical agent or agents at three distinct rates.
- the first or initial rate occurs when the pump 300 is implanted within the patient and only the initial water access port 130 is in fluid communication with the fluid environment of the pump's implant site within the patient.
- water from the implant site enters the pump at 130 , crosses the initial dose semipermeable membrane in the semipermeable membrane well 336 and comes into contact with the osmotic engine 306 , causing the engine 306 to swell and to push the piston 316 toward the second end 334 of the compartment 310 at an initial first rate.
- the physician may puncture the impermeable membrane of the first can 114 , thereby causing water form the implant site to enter therein, cross the first semipermeable membrane within the first semipermeable membrane well 146 and reach the osmotic engine 306 .
- the delivery rate of the pump 300 is now increased from its first, initial rate to a second, larger rate, as more water from the patient implant site is reaching the osmotic engine 306 , causing it to swell at a faster rate, thereby causing to piston 316 to travels within the compartment 310 at a corresponding second, faster rate.
- FIG. 39 is a cross-sectional view of the filter assembly 312 of FIG. 35 and FIG. 40 is a front view of the filter assembly 312 of FIG. 35.
- the filter assembly 312 may be (but need not be) shaped as a slanted and truncated circular cylinder.
- the filter assembly 312 defines a proximal end 313 and a distal end 315 .
- the assembly 312 further defines a pharmaceutical agent inlet 321 that emerges at the proximal end 313 and a pharmaceutical agent outlet 320 that emerges at the distal end of the filter assembly 312 . Between the inlet 321 and the outlet 320 , the filter assembly includes a filter 318 .
- the filter 318 may include a plug of porous material that defines a plurality of pores.
- the pores may range from about 2 microns in average pore size to about 80 microns in average pore size, for example.
- the average pore size of the porous material of the filter 318 may be selected within the range of about 5 microns to about 20 microns.
- the porous material of the filter 318 may be selected to be hydrophilic or hydrophobic, depending upon, for example, the nature of the pharmaceutical agent contained in the pump 300 .
- the pharmaceutical agent in the compartment 310 may be dissolved in an aqueous solution.
- the pharmaceutical agent in the compartment 310 of the pump 300 may be dissolved in a non-aqueous solution, such as alcohol (benzyl alcohol, for example).
- the filter assembly 318 may include a filter that is substantially hydrophobic in nature, which would allow the passage of a hydrophobic solution, but would not admit the passage of a (or a substantial amount of a hydrophilic solution such as water.
- the porous material 318 may have hydrophilic characteristics.
- the porous material 318 of the filter assembly 312 is hydrophilic, reliance is made on the pressure differential across the porous material 318 (higher on the proximal end 313 than on the distal end 315 end thereof, due to the pressure exerted by the osmotic engine 306 ) as well as on the pore size of the porous material 318 to limit the diffusion into the pump 300 .
- the pore size may be selected depending upon the magnitude of the pressure differential across the filter assembly 312 , the length of the filter 318 , the nature of the pharmaceutical agent to be delivered (for example, some pharmaceutical agent including large-sized protein molecules such contained in many pain medications may require a filter 318 defining relatively large size pores) and the aspect ratio of the filter 318 (ratio of aggregate pore size to length of filter 318 ), among other factors.
- Suitable materials for the porous material of the filter 318 may be obtained from, for example Millipore Corp. (http://www.millipore.com), Porex Corp. (http//:www.porex.com) and others.
- FIGS. 42, 43 and 44 show a perspective view, an exploded view and a top view of a single stage osmotic pump according to another embodiment of the present invention, with the top view of FIG. 44 showing internal components thereof in dashed lines.
- the pump 400 includes first and second housing halves 302 , 304 , filter assembly 312 , piston 316 , osmotic engine 306 and ring 308 , each of which being similar or identical to those structures in FIGS. 35-38 referenced by the same numerals. A detailed description of these structures is, therefore, omitted here.
- the single-stage pump 400 may include a semipermeable membrane enclosure 412 .
- the semipermeable membrane enclosure 412 may define a water access port 430 through which water from the patient implant site enters the pump 400 .
- the enclosure 412 also defines a water outlet port 438 , thorough which water comes into contact with the osmotic engine 306 .
- a semipermeable membrane Between the water inlet port 430 and the water outlet port 438 is disposed a semipermeable membrane.
- the water inlet port 430 may be covered by an impermeable membrane of stainless steel or titanium, for example.
- a saturated saline solution may be present between the impermeable membrane covering the water inlet port 430 and the semipermeable membrane within the enclosure 412 .
- Such a saturated saline solution maintains the semipermeable membrane in a hydrated state, and speeds up the initial delivery of the pharmaceutical agent contained in the compartment 310 of the pump 400 once the (optional) impermeable membrane covering the water inlet port 430 is breached.
- Such an impermeable membrane would be included in the pump 400 only if it was desired to implant the pump 400 in an inactive state and, at some later time, activate it so as to initiate the delivery of the pharmaceutical agent contained therein.
- the single stage pump 400 may also include the OFF switch features shown in FIGS. 32 and 33.
- the pharmaceutical agent compartment of the pumps according to the present invention may contain sufentanil, for example, and may also contain other medications.
- the pumps according to the present invention may be configured for intravascular, subcutaneous, epidural, intrathecal or intraventricular use. Table 1 below details exemplary maximum expected dosages of Sufentanil for above-listed uses. TABLE 1 Expected Maximum Dosage of Sufentanil ( ⁇ g/day) Intravascular 1500 Subcutaneous 1500 Epidural 500 Intrathecal 50 Intraventricular 25
- Table 2 below shows exemplary delivery schedules for pumps according to the present invention having a diameter of 1.8 cm and a compartment 310 having a capacity of 200 mg, a diameter of 2.8 cm and a compartment 310 having a capacity of 500 mg and a diameter of 5.0 cm and a compartment 310 having a capacity of 2000 mg over selected delivery rates (in mg/day) ranging from 0.50 mg/day to 20.0 mg/day.
- the present invention may be implanted under the patient's skin in an outpatient setting.
- the implantation procedure may be performed with a local anesthetic and may be carried out in as little as 15-20 minutes, for example.
- a small 0.5 to 0.75 inch incision may be all that is required, which incision may later be closed with one or more STERI-STRIP® skin closure devices or sutures, for example.
- the thin, circular shape of the pumps according to the present invention facilitates placement thereof in a number of locations throughout the patient's body, including the chest wall, the lower back, the arms and legs, the neck and even under the scalp, to identify a few exemplary locations.
Abstract
A pump, includes a pump engine; a compartment adapted to store a fluid, the compartment being disposed at least partially around the pump engine, and a piston disposed within the compartment, the compartment and the engine being configured to cause the piston to travel within the compartment along an arcuate path and to force a volume of the fluid out of the pump.
Description
- This application is a continuation under 35 USC §120 of copending and commonly assigned U.S. patent application Ser. No. 09/838,662 filed on Apr. 19, 2001.
- 1. Field of the Invention
- The present invention relates generally to the field of drug delivery systems. In particular, the present invention relates to implantable osmotic pump systems.
- 2. Description of the Related Art
- Since the beginning of modern medicine, drugs have been administered orally. Patients have taken pills as recommended by their physician. The pills must pass through the digestive system and then the liver before they reach their intended delivery site (e.g., the vascular system). The actions of the digestive tract and the liver typically reduce the efficacy of medication by about 33%. Furthermore, oral medications must be administered by the patient. Patient compliance to the prescribed delivery profile is often poor. Studies suggest that 40% of patients do not comply with their oral medication consumption instructions. This causes two concerns. First, patients who do not take their medication as instructed are not maintaining blood drug levels within the therapeutic window and are therefore not receiving adequate therapy for their disease. A second, worse scenario than receiving too little medication occurs when the patient may be taking too much medication either by accident or purposefully in order to make up for a missed dose. Both of these patient-controlled scenarios can be dangerous to the patient, and at a minimum may prolong or aggravate their disease. Subcutaneous drug delivery and intravenous drug delivery have the advantage of bypassing the acidic and enzymatic action of the digestive system. Unfortunately, IV administration requires the use of a percutaneous catheter or needle to deliver the drug to the vein. The percutaneous site requires extra cleanliness and maintenance to minimize the risk of infection. Infection is such a significant risk that IV administration is often limited to a number of weeks, at most. In addition, the patient must wear an external pump connected to the percutaneous catheter if the therapy is intended to last longer than a few hours and the patient desires to be ambulatory. Subcutaneous drug delivery can be either partially implanted or totally implanted. Partially implanted systems rely on a percutaneous catheter or needle stick to deliver the medication, therefore, partially implanted systems have the same limitations as IV systems. Totally implanted systems have fewer maintenance requirements and are far less prone to infection than IV or partially implanted systems.
- In the 1970s, a new approach toward sustained drug delivery was commercialized for animal use only. The driving force of such pumps was based upon a new approach utilizing the principle of osmosis. A recent example of such a pump is described listed in U.S. Pat. No. 5,728,396. This patent discloses an implantable osmotic pump that achieves a sustained delivery of leuprolide. The pump includes a right-cylindrical impermeable reservoir that is divided into a water-swellable agent chamber and a drug chamber, the two chambers being divided by a movable piston. Fluid from the body is imbibed through a semipermeable membrane into the water-swellable agent chamber. As the water-swellable agent in the water-swellable agent chamber expands in volume, it pushes on the movable piston, which correspondingly decreases the volume of the drug chamber and causes the drug to be released through a diffusion outlet at a substantially constant rate.
- A limitation of the osmotic pump disclosed in the above-identified patent, however, is that its infusion rate cannot be adjusted once it is implanted. This is acceptable for medications that do not need rate adjustment, but often physicians desire to adjust the infusion rate based on the clinical status of the patient. One example of when a physician would want to increase the infusion rate is in the field of pain management. Osmotic pumps can be used to deliver medication to treat pain lasting over an extended period of time. Pain, however, often increases with time, and sometimes patients become tolerant to pain medications; therefore, more medication is needed to effectively treat the pain. The system disclosed in the above-identified patent does not allow a rate increase after implantation, so the physician must surgically remove the current implant and implant an additional pump to deliver the correct dosage. However, the prospect of yet another surgical procedure may cause many patients to forego the potential benefits of the larger dose and may also cause their physicians to advise against the initial procedure altogether.
- The aspect ratio of such cylindrical osmotic pump delivery devices is large, and often not compatible with the human body. Indeed, the human body does not have naturally-formed right-cylindrical cavities in which to implant such devices in the patient, in an unobtrusive and comfortable manner.
- What are needed, therefore, are improved osmotic pumps. What are also needed are improved implantable osmotic pumps that conform to the patient's anatomy and that more closely match the topology of the implant site. Also needed are novel implantable osmotic pumps for long term delivery of a pharmaceutical agent that do not rely upon a right-cylindrical pharmaceutical agent compartment and/or conventional cylindrical pistons. Also needed are implantable pumps that enable the physician to increase the dose of pharmaceutical agent delivered to the patient without, however, removing the pump from the implant site.
- It is an object of the present invention, therefore, to provide improved pumps. Another object of the present invention is to provide improved implantable osmotic pumps that conform to the patient's anatomy and that more closely match the topology of the implant site. A still further object is to provide novel implantable osmotic pumps for long term delivery of a pharmaceutical agent that do not rely upon a right-cylindrical pharmaceutical agent compartment and/or conventional cylindrical pistons. Preferably, such improved pumps should enable the physician to increase the dose of pharmaceutical agent delivered to the patient without removing the pump from the implant site.
- In accordance with the above-described objects and those that will be mentioned and will become apparent below, an implantable osmotic pump for delivering a pharmaceutical agent to a patient, includes a catheter; an osmotic engine; a pharmaceutical agent compartment; a volume of pharmaceutical agent that includes Sufentanil within the pharmaceutical agent compartment, and a piston disposed within the compartment, the compartment being configured such that the osmotic engine causes the piston to travel within the compartment along an arcuate path and deliver the pharmaceutical agent through the catheter when the pump is implanted in the patient, wherein the pump is configured for: a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the catheter is placed intraventricularly; a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the catheter is placed intrathecally; a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the catheter is placed epidurally; a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the catheter is placed subcutaneously, and a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the catheter is placed intravascularly.
- The compartment may be disposed at least partially around the osmotic engine. The osmotic engine may include a base, a cylindrical wall attached to the base and a free end opposite the base.
- The pump may further include a housing configured to enclose at least the osmotic engine and the compartment. The housing may include a first housing half and a second housing half that mates with the first housing half. Each of the first and second housing halves may define a saucer shape. Each of the first and the second housing halves may be substantially circular in shape. The first housing half may define a substantially circular opening. The pump may further include a membrane enclosure, the membrane enclosure being partially surrounded by the osmotic engine and may include an initial dose semipermeable membrane that may be configured to allow water from the patient to reach the osmotic engine when the pump is implanted. The pump may be configured to deliver an initial dose of the pharmaceutical agent to the patient at a selected initial infusion rate, the selected initial infusion rate being related to a thickness, a composition and/or a surface area of the initial dose semipermeable membrane. The initial dose semipermeable membrane may be fitted with an initial dose impermeable membrane that initially seals the initial dose semipermeable membrane. The pump may further include a volume of a saturated saline solution between the initial dose semipermeable membrane and the initial dose semipermeable membrane. The pump may further include a dose escalation assembly fitted in the membrane enclosure, the dose escalation assembly being adapted to selectively increase an amount of water from the patient that reaches the osmotic engine when the pump is implanted. The dose escalation assembly may include a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached. The dose escalation assembly may include: a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached, and a second impermeable membrane configured to enable water from the patient to reach the osmotic engine through a second fluid path only after being breached, the first path being distinct from the second path. The first and second impermeable membranes may be disposed in the membrane enclosure in a stacked configuration in which the first impermeable membrane must be breached before the second impermeable membrane can be breached. The first fluid path may include a first semipermeable membrane and the second fluid path may include a second semipermeable membrane that is distinct from the first semipermeable membrane. The pump may be configured to deliver a first dose of the pharmaceutical agent to the patient at a selected first infusion rate and a second dose of the pharmaceutical agent to the patient at a selected second infusion rate that may be greater than the first infusion rate, the selected first and second infusion rates being related to a thickness, a composition and/or a surface area of the first and second semipermeable membranes, respectively. The osmotic engine may include a hygroscopic salt, for example. The osmotic engine may include an absorbent polymer. The absorbent polymer may include a material selected from a group including poly(acrylic acid), potassium salt; poly(acrylic acid), sodium salt; poly(acrylic acid-co-acrylamide), potassium salt; poly(acrylic acid), sodium salt-graft-poly(ethylene oxide); poly (2-hydroxethyl methacrylate); poly(2-hydroxypropyl methacrylate) and poly(isobutylene-co-maleic acid) or derivatives thereof.
- The compartment may have a substantially constant inner diameter over a length thereof. The compartment may have a non-constant inner diameter over a length thereof. The catheter may include a radiopaque tip. The piston may include one of a sphere, an elastomeric cylinder and an elastomeric conical section. The piston may include at least one of stainless steel, a refractory metal, plastic, nylon and rubber. The sufentanil may be at a concentration up to about 500,000 μg/mL, for example. The dose escalation assembly may include: a first saturated saline solution between the first impermeable membrane and the first semipermeable membrane, and a second saturated saline solution between the second impermeable membrane and the second semipermeable membrane.
- The present invention, according to another embodiment thereof, is a method of delivering a pharmaceutical agent to a patient, comprising steps of: implanting a pump into the patient, the pump including a pump engine and a compartment adapted to store a pharmaceutical agent, and causing a piston to travel a distance within the compartment along an arcuate path and to deliver a dose of pharmaceutical agent out of the compartment.
- The implanting step may be carried such that the pharmaceutical agent is delivered one of intravascularly, subcutaneously, epidurally, intrathecally and intraventricularly. The pharmaceutical agent may include Sufentanil and the pump may be configured for: a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intraventricularly; a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intrathecally; a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered epidurally; a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered subcutaneously, and a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intravascularly. Travel of the piston within the compartment may cause a delivery of a volume up to about 20 μL/day over a treatment period, for example. The method may further comprise the step of selectively increasing the dose in a stepwise manner over a treatment period without removing the pump from the patient. The pump engine may include an osmotic engine and the pump may include an initial dose semipermeable membrane initially exposed to the patient and at least one second semipermeable membrane initially not exposed to the patient and the increasing step may include a step of selectively exposing the at least one second semipermeable membrane to the patient. The pump the engine may include an osmotic engine in fluid communication with the piston and the causing step may include a step of increasing a volume of the osmotic engine.
- The present invention, according to yet another embodiment thereof, is a pump, comprising: a pump engine; a compartment adapted to store a fluid, the compartment being disposed at least partially around the pump engine, and a piston disposed within the compartment, the compartment and the engine being configured to cause the piston to travel within the compartment along an arcuate path and to force a volume of the fluid out of the pump.
- The pump engine may include an osmotic engine. The fluid may include a pharmaceutical agent. A catheter may be coupled to the compartment. The pump may be configured to be fully implantable in a body and pump engine and the compartment may be enclosed in a biocompatible pump housing. The pump may include a dose escalation assembly, the escalation assembly being configured to selectively increase the dose of fluid delivered. The dose escalation assembly may include means for increasing the dose delivered in a stepwise manner. The piston may include one of a sphere, an elastomeric cylinder and an elastomeric conical section.
- For a further understanding of the objects and advantages of the present invention, reference should be made to the following detailed description, taken in conjunction with the accompanying figures, in which:
- FIG. 1 is a perspective view of the osmotic pump according to an embodiment of the present invention.
- FIG. 2 is an exploded view of the osmotic pump according to an embodiment of the present invention, showing the major components thereof.
- FIG. 3 is a plan view of the osmotic pump according to an embodiment of the present invention in which the first half of the housing has been removed.
- FIG. 4 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines BB′.
- FIG. 5 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines AA′.
- FIG. 6 is a plan view of the second half of the osmotic pump housing, according to an embodiment of the present invention.
- FIG. 7 is a cross sectional view of the second half of the osmotic pump housing, taken along lines CC′.
- FIG. 8 is a perspective view of the first half of the osmotic pump housing according to an embodiment of the present invention.
- FIG. 9 is a plan view of the first half of the osmotic pump housing of FIG. 8.
- FIG. 10 is a cross-sectional view of the first half of the osmotic pump housing of FIG. 9, taken along lines DD′.
- FIG. 11 is a plan view of an embodiment of the membrane enclosure, according to an embodiment thereof.
- FIG. 12 is a perspective view of the membrane enclosure of FIG. 11, showing the semipermeable membrane wells in dashed lines.
- FIG. 13 is a plan view of an impermeable membrane can of an osmotic pump according to an embodiment of the present invention, showing the internal surface and through bore thereof in dashed lines.
- FIG. 14 shows a side view of the impermeable membrane can of FIG. 13.
- FIG. 15 is a plan view of the osmotic engine of the osmotic pump, according to an embodiment of the present invention.
- FIG. 16 is a side view of the osmotic engine of FIG. 15.
- FIG. 17 is a plan view of the coiled tube, according to an embodiment of the present invention.
- FIG. 18 is a cross-sectional view of the tube of FIG. 17, taken along line EE′.
- FIG. 19 is a cross-sectional view of the coiled tube of FIG. 17, taken along line FF′.
- FIG. 20 illustrates the tube coupled to a catheter, according to an embodiment of the present invention.
- FIG. 21 illustrates the distal tip of the catheter of FIG. 20, according to an embodiment of the present invention.
- FIG. 22 illustrates the proximal end of the catheter of FIG. 20, according to an embodiment of the present invention.
- FIG. 23 shows an embodiment of a piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 24 shows a further embodiment of a piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 25 shows a further embodiment of still another piston within the coiled pharmaceutical agent compartment, according to an embodiment of the present invention.
- FIG. 26 shows a first step of a method by which the impermeable membrane of the first impermeable membrane may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 27 shows a second step of a method by which the impermeable membrane of the first impermeable membrane may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 28 shows a third step of a method by which the impermeable membrane of the first impermeable membrane can may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 29 shows a fourth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 30 shows a fifth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 31 shows a sixth step of a method by which the impermeable membrane of the second impermeable membrane can may be breached so as to further escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention.
- FIG. 32 is a plan view of another embodiment of the membrane enclosure, according to the present invention, showing the OFF feature of the present invention.
- FIG. 33 is a perspective view of the membrane enclosure of FIG. 32, showing the semipermeable membrane wells in dashed lines and the OFF switch feature of the present invention.
- FIG. 34 is an exploded view of another embodiment of an osmotic pump according to the present invention.
- FIG. 35 is an exploded view of a three-stage osmotic pump, according to another embodiment of the present invention.
- FIG. 36a is a top view of a three stage osmotic pump according to the present invention, showing the internal structure thereof in dashed lines.
- FIG. 36b is a reduced-size (relative to FIG. 36a) top view of a three stage osmotic pump, showing selected exemplary dimensions thereof.
- FIG. 37 is a cross-sectional view of a three stage osmotic pump according to the present invention, taken along cross-sectional line BB′ of FIG. 36.
- FIG. 38 is a cross-sectional view of a three stage osmotic pump according to the present invention, taken along cross-sectional line AA′ of FIG. 36.
- FIG. 39 is a cross-sectional view of the
filter assembly 312 of FIG. 35. - FIG. 40 is a front view of the
filter assembly 312 of FIG. 35. - FIG. 41 is a cross-sectional view of a piston, according to an embodiment of the present invention.
- FIG. 42 is a perspective view of a single stage osmotic pump according to another embodiment of the present invention.
- FIG. 43 is an exploded view of a single stage osmotic pump according to the present invention.
- FIG. 44 is a top view of a single stage osmotic pump according to the present invention, showing internal components thereof in dashed lines.
- FIG. 1 is a perspective view and FIG. 2 shows an exploded view of the
pump 100 according to an embodiment of the present invention. Considering FIGS. 1 and 2 collectively, thepump 100 includes apump engine 108 and a substantially toroidal compartment around theengine 108. The toroidal compartment is bounded by aninner radius 207 and anouter radius 208 and is adapted to contain a fluid, such as a pharmaceutical agent. According to an embodiment of the present invention, the pharmaceutical agent compartment is tube-shaped and is defined by aninner lumen 110 of atube 109 that may be coiled at least partially around theosmotic engine 108. Thetube 109 has aproximal end 184 and adistal end 186. Thetube 109 may include or be formed of, for example, polyimid. Apiston 162 is disposed in the tube-shapedcompartment 110. The piston is adapted to travel (in the direction from theproximal end 184 to thedistal end 186 of the tube 109) within the tube-shapedcompartment 110 and to cause a volume of fluid to be forced out of thedistal end 186 of thetube 109. As shown in FIG. 1, acatheter 102 may be coupled to thedistal end 186 of thetube 109, to enable the fluid forced out thedistal end 186 of thetube 109 to be delivered to the intended delivery site within the patient. In one embodiment of the present invention, thepump engine 108 includes an osmotic engine. Thepump 100 may further include apump housing 101 that is configured to enclose (at least) thepump engine 108 and thetube 109. As shown in FIG. 2, thepump housing 101 may include afirst housing half 106 and a matingsecond housing half 104. According to an embodiment of the present invention, the first and secondpump housing halves second housing halves first housing half 106 may further define anopening 140, which may be circular in shape. - The present invention will now be described in terms of an implantable osmotic pump for delivering a pharmaceutical agent to a patient, although the present invention is not so limited. The pump and/or the
catheter 102 may be implanted intravascularly, subcutaneously, epidurally, intrathecally and/or intraventricularly, for example. As shown in FIG. 2 as well as in FIGS. 15 and 16, the pump engine 108 (referred to hereafter asosmotic engine 108, although the present invention is not limited to osmotic-type pump engines) may be shaped like hollow, open-ended right cylinder. Theosmotic engine 108 is hygroscopic and may include a salt block or a “salt wafer” and/or may include an absorbent polymer, such as poly(acrylic acid), potassium salt; poly(acrylic acid), sodium salt; poly(acrylic acid-co-acrylamide), potassium salt; poly(acrylic acid), sodium salt-graft-poly(ethylene oxide); poly (2-hydroxethyl methacrylate) and/or poly(2-hydroxypropyl methacrylate) and poly(isobutylene-co-maleic acid). Suitable absorbent polymers are available from Aldrich, Inc. of Milwaukee, Wis., for example. Theosmotic engine 108 may include a base that may be disposed in a correspondingly shaped depression defined in thesecond housing half 104 and a cylindrical wall attached to the base. - According to an embodiment of the present invention, the
pump 100 may include a generally cylindrical-shapedmembrane enclosure 112. Themembrane enclosure 112 may be fitted within and partially surrounded by thepump engine 108. Themembrane enclosure 112 is dimensioned to closely fit theopening 140 defined in thefirst housing half 106. Themembrane enclosure 112 may include an initial dose semipermeable membrane (formed of or including cellulose acetate, for example), as shown in FIG. 5, to create a fluid path for water through the initialwater access port 130 defined in themembrane enclosure 112 to theosmotic engine 108. The initialwater access port 130 may be spanned by a thinimpermeable membrane 182, thereby defining an interstitial space between the initial dose semipermeable membrane and the impermeable membrane. This interstitial space may be filled with a saturated saline solution, to keep the initial dose semipermeable membrane fully hydrated prior to implantation of thepump 100 in a patient (not shown). Prior to implantation, the physician may breach theimpermeable membrane 182 spanning the initialwater access port 130 to allow water from the patient to enter the initial dose semipermeable membrane well 150 (see FIG. 12) and migrate across the initial dose semipermeable membrane 134 (see FIG. 5) to reach theosmotic engine 108. In this manner, the initialwater access port 130, the thinimpermeable membrane 182 and the saturated saline solution effectively form a pump ON switch. Indeed, after implantation of the pump but before breaching the thinimpermeable membrane 182, thepump 100 does not deliver any pharmaceutical agent to the patient. It is only after breaching the thinimpermeable membrane 182 that the pump becomes effective to initiate delivery of the contained pharmaceutical agent to the patient. The saturated saline solution between theimpermeable membrane 182 and the underlying initial dosesemipermeable membrane 150 insures that the onset of delivery of the pharmaceutical agent is not delayed by the time required for the initial dosesemipermeable membrane 150 to hydrate. - The
membrane enclosure 112 may also define a primarywater access port 132 that may be (but need not be) concentric with the circumference of themembrane enclosure 112. A dose escalation assembly may fit within the primarywater access port 132. The dose escalation assembly, according to the present invention, is adapted to selectively increase the amount of water from implantation site within the patient that reaches theosmotic engine 108. The dose escalation assembly may include one or more impermeable membrane cans fitted within the primarywater access port 132 of themembrane enclosure 112. In the embodiment of FIG. 2, the dose escalation includes a first impermeable membrane can 114 stacked upon a second impermeable membrane can 116 whose structure and function is described hereunder. - Reference is now made to FIGS. 3-5, in which FIG. 3 is a plan view of the osmotic pump according to an embodiment of the present invention in which the first half of the housing has been removed, FIG. 4 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines BB′ of FIG. 3 and FIG. 5 is a cross sectional view of the osmotic pump of FIG. 3, taken along lines AA′. FIG. 3 shows the
tube 109 coiled around theosmotic engine 108 from theproximal end 184 to the distal end thereof, shown at 186. Thedistal end 186 of the coiledtube 109 may be fitted with acatheter ID tube 118 that facilitates the coupling of thecatheter 102 to thedistal end 186 of thetube 109. As shown in FIG. 5, the initialwater access port 130 may lead to an initial dosesemipermeable membrane 134 within themembrane enclosure 112. Themembrane enclosure 112 is configured to enable water from the patient to flow into the initialwater access port 130, to migrate across the initial dosesemipermeable membrane 134 to reach theosmotic engine 108. As the water reaches theosmotic engine 108, theengine 108 swells in volume and increases the osmotic pressure differential across the initial dosesemipermeable membrane 134 and pushes thepiston 160 within the tube-shaped compartment defined by thetube 109 toward thedistal end 186 thereof, as the expansion of theosmotic engine 108 is constrained to within the tube-shapedcompartment 110. In so doing, thepiston 160 displaces a volume of pharmaceutical agent within the tube-shapedcompartment 110, which displaced volume of pharmaceutical agent is delivered out of thedistal end 186 of thetube 109. The pharmaceutical agent is delivered at a selected initial infusion rate that is related to the thickness, composition and surface area of the initial dosesemipermeable membrane 134. In the case wherein the initial dosesemipermeable membrane 134 is implanted in a fully hydrated state, the pharmaceutical agent within the tube-shaped compartment is quickly delivered to the patient at the selected initial infusion rate. If the initial dosesemipermeable membrane 134 is not pre-hydrated, the delivery of the pharmaceutical agent may be delayed until themembrane 134 becomes at least partially hydrated from water from the patient implant site. Until at least the firstimpermeable membrane cans 114 is breached, the only water that reaches theosmotic engine 108 enters thepump 100 through the initialwater access port 130 to cross the initial dosesemipermeable membrane 134. - As shown in FIG. 4, the
membrane assembly 112 includes a firstsemipermeable membrane 120 and a secondsemipermeable membrane 124. The diameter of thesemipermeable membranes semipermeable membrane 120 may be (but need not be) vertically offset from the secondsemipermeable membrane 124 in themembrane enclosure 112. Reference is now made to FIGS. 13 and 14, of which FIG. 13 is a plan view of an impermeable membrane can 114, 116 and of which FIG. 14 is a side view of the impermeable membrane can 114, 116 of FIG. 13. As shown therein, thecans cylindrical sidewall 154 and a through bore defined therein. Specifically, the sidewall of the first impermeable membrane can 114 defines a first throughbore 122 and the sidewall of the second impermeable membrane can 116 defines a second throughbore 126. An impermeable membrane 152 (shown in FIGS. 13 and 14 in its intact state) spans one of the free ends of each of thecans impermeable membranes 152, according to the present invention, are impermeable at least to water from the patient implant site and are configured to be easily breached by the physician, as is detailed below. Theimpermeable membranes 152 may include or be formed of most any water impermeable material that is biologically inert, such as titanium and/or stainless steel, coated platinum or platinum-iridium for radiopacity, for example. Theimpermeable membranes 152 of the first andsecond cans impermeable membranes 152 may alternatively include polyethylene, PET, PETG or PETE, for example. Preferably, theimpermeable membranes 152 are radiopaque, so as to be visible under fluoroscopy, once thepump 100 is implanted. For example, a layer of radiopaque material may be sputtered or otherwise deposited on theimpermeable membranes 152, to render them visible under fluoroscopy. Preferably, theimpermeable membranes 110 are adapted to be breached by the physician or clinician, using a dose escalation pen (or a lancet or stylet as shown in FIGS. 26-31), or some other functionally similar device. Theimpermeable membranes 152 of the first and secondimpermeable membrane cans semipermeable membranes semipermeable membranes - Returning now to FIGS. 3-5, the first and second
impermeable membrane cans membrane enclosure 112 such that the respective throughbores semipermeable membranes bore 122 defined in the first impermeable membrane can 114 is aligned with the firstsemipermeable membrane 120 and the second throughbore 126 defined in the second impermeable membrane can 116 is aligned with the secondsemipermeable membrane 124. Moreover, theimpermeable membrane 152 of the first impermeable membrane can 114 is disposed adjacent the primarywater access port 132, whereas the secondimpermeable can 116 is disposed under the first impermeable membrane can 114 and oriented such that the impermeable membrane thereof is immediately adjacent the first impermeable membrane can 114. Although the present figures show thepump 100 of the present invention equipped with twoimpermeable membrane cans - FIG. 6 is a plan view of the
second half 104 of theosmotic pump housing 101, according to an embodiment of the present invention and FIG. 7 is a cross sectional view thereof, taken along lines CC′. As shown therein, thesecond half 104 of thepump housing 101 may have a generally saucer-like shape. Indeed, thesecond half 104 of thehousing 101 may have a generally circular outline and may define abulge 136 therein to accommodate a portion of theosmotic engine 108 therein. The rim of the second half 104 (See FIG. 10) of thepump housing 101 also defines anindentation 138 adapted to mate with a corresponding feature defined by the rim of thefirst half 106 of thepump housing 101. FIG. 8 is a perspective view of thefirst half 106 of theosmotic pump housing 101 according to an embodiment of the present invention, whereas FIG. 9 is a plan view and FIG. 10 is a cross-sectional view thereof, taken along lines DD′. As shown in the perspective view of FIG. 10, anopening 140 is defined in the also generally saucer-shapedfirst half 106 of theosmotic pump housing 101. Theopening 140 may be centered in thehousing half 106 and concentric with the generally circular outline thereof, as shown in FIG. 9. Theopening 140 is preferably dimensioned so as to closely fit themembrane enclosure 112. As shown in FIG. 10, thefirst half 106 of thepump housing 101 may define abulge 144 that increases the interior volume of thepump 100 when the first andsecond housing halves - FIG. 11 is a plan view of an embodiment of the
membrane housing 112, according to an embodiment thereof, whereas FIG. 12 is a perspective view of the membrane housing of FIG. 11, showing the semipermeable membrane wells in dashed lines. Considering now FIGS. 11 and 12 collectively, themembrane enclosure 112 may be shaped as a cylinder dimensioned to fit within theosmotic engine 108 and theopening 140 in thefirst housing half 106. The primarywater access port 132 may be a bore partially through themembrane enclosure 112. However, to best control the flow of water form the patient implant site to theosmotic engine 108, the bore defined within themembrane enclosure 112 should not run the entire length of themembrane enclosure 112. Indeed, the only water paths from the implant site to the osmotic engine should be through the initial dose semipermeable membrane well 150, through the first semipermeable membrane well 146 and/or through the secondsemipermeable membrane well 150. In contrast, the combination of the initialwater access port 130 and the initial dose semipermeable well 150 runs the entire length of themembrane enclosure 112, as also shown in FIG. 5. Indeed, once thepump 100 is implanted in the patient and any impermeable membrane that may span the initialwater access port 130 is breached, a water path to theosmotic engine 108 may be defined straight through themembrane enclosure 112, as the water from the implant site migrates across the initial dose semipermeable membrane (shown at 134 in FIG. 5) fitted within the initial dosesemipermeable membrane well 150. - First and second
semipermeable membranes 120, 124 (shown in FIG. 4) are fitted within the first and secondsemipermeable membrane wells impermeable membrane 152 of the first impermeable membrane can 114 is breached (as shown at 176 in FIGS. 28, 29 and 31), water from the implant site may enter theprimary access port 132 and travel through the first throughbore 122 of the first impermeable membrane can 114. From there, the water may travel through afirst passageway 188, defined between primarywater access port 132 and firstsemipermeable membrane well 146. After crossing the firstsemipermeable membrane 120 disposed in the well 146, the water reaches theosmotic engine 108. This first water path is shown at 178 in FIGS. 28, 29 and 31. As the water reaches theosmotic engine 108, theengine 108 swells in volume due to the osmotic pressure differential across the firstsemipermeable membrane 120 and pushes thepiston compartment 110 defined within thetube 109 toward thedistal end 186 thereof. In so doing, thepiston compartment 110, which displaced volume of pharmaceutical agent is delivered out of thedistal end 186 of thetube 109. The pharmaceutical agent is delivered at a selected first infusion rate that is related to the thickness, composition and surface area of the firstsemipermeable membrane 120 and that of the initial dosesemipermeable membrane 134. - Similarly, when the
impermeable membrane 152 of the second impermeable membrane can 116 is breached (as shown at 177 in FIGS. 28, 29 and 31), water from the implant site may enter theprimary access port 132 and travel through the second throughbore 126 of the second impermeable membrane can 116. From there, the water may travel through asecond passageway 190, defined within theenclosure 112 between the primarywater access port 132 and the secondsemipermeable membrane well 148. After crossing the secondsemipermeable membrane 124 disposed in the well 148, the water reaches theosmotic engine 108. This water path is shown at 180 in FIG. 31. As the water reaches theosmotic engine 108, theengine 108 swells in volume due to the osmotic pressure differential across the secondsemipermeable membrane 124 and pushes thepiston compartment 110 defined by thetube 109 toward thedistal end 186 thereof. In so doing, thepiston 160 displaces a volume of pharmaceutical agent within the tube-shapedcompartment 110, which displaced volume of pharmaceutical agent is delivered out of thedistal end 186 of thetube 109. The pharmaceutical agent is delivered at a selected second infusion rate that is related to the thickness, composition and surface area of the secondsemipermeable membrane 124, the thickness, composition and surface area of the firstsemipermeable membrane 120 and the thickness, composition and surface area of the initial dosesemipermeable membrane 134. Indeed, the infusion rate of thepump 100 is related to which of thesemipermeable membranes semipermeable membrane 134 is exposed to the patient, the infusion rate may be related only to the characteristics of the initial dosesemipermeable membrane 134. If both the initial dosesemipermeable membrane 134 and the firstsemipermeable membrane 120 are exposed to the patient, the pump infusion rate may be related to the characteristics of both the initial dose and firstsemipermeable membranes pump 100 of the present invention in the state wherein both the initial dosesemipermeable membrane 134 and the firstsemipermeable membrane 120 are breached, may be approximated as the sum of the individual infusion rates contributed by each of thesemipermeable membranes semipermeable membrane 134, the firstsemipermeable membrane 120 and the secondsemipermeable membrane 124 are exposed to the patient, the pump infusion rate may be related to the characteristics of the initial dose, the first and the secondsemipermeable membranes impermeable membranes semipermeable membranes - FIG. 17 is a plan view of the coiled
tube 109, according to an embodiment of the present invention, FIG. 18 is a cross-sectional view of thetube 109 of FIG. 17, taken along line EE′ and FIG. 19 is a cross-sectional view thereof, taken along line FF′. According to the present invention, thepiston 160 may initially (upon implantation) be disposed within the tube-shapedcompartment 110 near theproximal end 184 of thetube 109. As the osmotic engine expands in volume, the only available volume for such expansion is within the tube-shapedcompartment 110. Therefore, the expansion of theosmotic engine 108 forces thepiston 160 to travel through the coiledtube 109 in the direction ofarrow 166, which causes a volume of pharmaceutical agent to be delivered to the patient out of thedistal end 186 of thetube 109. A catheter ID (inner diameter)tube 118 may be fitted onto thedistal end 186 of thetube 109, which facilitates coupling thecatheter 102 thereto. As shown, thetube 109 may be coiled a number of times around themembrane enclosure 112. In the embodiment shown in FIGS. 17-19, thetube 109 is coiled four times around the membrane enclosure 112 (not shown in FIGS. 17-19), although a lesser or greater number of coils may readily be implemented. - FIG. 20 illustrates the
tube 109 coupled to acatheter 102, according to an embodiment of the present invention. FIG. 21 illustrates the distal tip of the catheter of FIG. 20, according to an embodiment of the present invention and FIG. 22 illustrates the manner in which the catheter may couple to thecatheter ID tube 118. In FIG. 20, the outline of thepump housing 101 is shown for reference purposes. Thecatheter 102 is used to deliver the pharmaceutical agent from thecatheter ID tube 118 to the target area within the patient's body. Thecatheter 102 may be visible under fluoroscopy over its length, thereby enabling the physician to trim the catheter to the desired length. Alternatively, thecatheter 102 may include distal radiopaque markers, for example. As shown in FIG. 21, thedistal tip 158 of thecatheter 102 may included a rounded, atraumatic tip. A plurality ofpharmaceutical agent openings 158 may be defined through the catheter wall, from the internal lumen thereof to the patient. As shown in FIG. 22, the catheter ID may be fitted over thecatheter ID tube 118 using a friction fit and/or suitable biocompatible adhesive(s), for example. Any suitable radio opaque material may be used to render all or a portion or selected portions of thecatheter 102 radio opaque. For example, thecatheter 102 may be formed of silicone or polyurethane and may be doped with barium sulfate, for example. The length of thecatheter 102 may be most any therapeutically effective length. A longer length, however, increases the dead space therein and delays the effusion of the pharmaceutical agent into the patient, as it will take longer for the agent to travel the length thereof. For example, thecatheter 102 may be about 5 cm to about 100 cm in length. More preferably, thecatheter 102 may be about 10 cm to about 30 cm in length. More preferably still, the catheter 012 may be about 15 cm to about 25 cm in length. For example, thecatheter 102 may be about 20 cm in length. The internal diameter (ID) of the infusion lumen of thecatheter 102 may be selected within the range of about 0.001 inches to about 0.010 inches. The walls of thecatheter 102 may be about 0.001 inches to about 0.006 inches in thickness. According to an embodiment of the present invention, the outer diameter (OD) of thecatheter 102 may be selected between about 0.024 inches and about 0.066 inches in thickness, for example. - FIGS. 23-25 are cross sections of the
tube 109, showing various designs for the piston within the tube shapedcompartment 110. Considering now FIGS. 23-25 collectively, the piston of theosmotic pump 100 of the present invention may be spherical, as shown at 160, cylindrical as shown at 162 or may approximate a conical section as shown at 163, although other shapes are possible. A spherical shape minimizes the contact points of thepiston 160 with the tube-shapedcompartment 110, thereby enabling thepiston 160 to travel through thecompartment 110, even as the radius of curvature thereof changes form theproximal end 184 to the distal end of thetube 109.Reference 170 represents slurry from theosmotic engine 108. Indeed,reference 170 may be considered to be an extension of theosmotic engine 108, as it swells with water from the patient implant site through thesemipermeable membranes osmotic engine 108 swells in volume, it exerts aforce 168 on thepiston compartment 110 in the direction ofarrow 166. In so doing, thepiston pharmaceutical agent 164. Thepiston piston 162 may be formed of an elastomeric substance, such as butyl rubber, for example. Such acylindrical piston 162 may then deform to match the radius of curvature of the tube-shapedcompartment 110. The inner diameter of the tube 109 (that is, the diameter of the tube-shaped compartment 110) may be constant over the length of thetube 109 or may become larger or smaller over its length. In the latter case, thepiston 163 may assume a truncated conical shape, in which a proximal end thereof is smaller than a distal end thereof (or vice-versa), to match the change in inner diameter of the tube-shapedcompartment 110. To prevent thetube 109 from compressing, binding and/or kinking as theosmotic engine 108 swells, thecoiled tube 109 may be encased in a hard substance, such as epoxy, for example. - FIG. 26-28 shows steps of a method by which the
impermeable membrane 152 of the first impermeable membrane can 114 may be breached so as to escalate a dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention. FIG. 29-31 shows further steps of the method by which theimpermeable membrane 152 of the second impermeable membrane can 116 may be breached so as to further escalate the dose of pharmaceutical agent delivered to the patient, according to an embodiment of the present invention. While any device may be used to breach theimpermeable membranes 152, a dose escalation pen orstylet 172 similar to that shown in FIGS. 26-31 may be advantageously used. Anactuator 192, such as a thumb actuated wheel, may be coupled to a pointedextendible portion 200 of thepen 172. Actuating theactuator 192 may cause the pointed andextendible portion 200 to extend in length from afirst length 202 shown in FIGS. 26-28, to asecond length 204 shown in FIGS. 29-31. At some time after implantation of thepump 100, the patient may require a greater dose of pharmaceutical agent than provided by the initial dose, which initial dose is driven by theosmotic engine 108 swelling in response to water entering the initialwater access port 132. Without removing thepump 100 from the patient, the physician may, according to the present invention, use a dose escalation pen or stylet to increase the effusion rate of the pharmaceutical agent from thepump 100 in a simple office or outpatient procedure. - For clarity of illustration, only the first and second
impermeable membrane cans pump 100 are shown in FIGS. 26-31. In the state illustrated in FIG. 26, theimpermeable membranes 152 prevent any water from the patient implant site from reaching the first and secondsemipermeable membranes dose escalation pen 172 in a configuration wherein the pointedextendible portion 200 thereof is extended only to thefirst length 202. By inserting theportion 200 through the patient's skin under fluoroscopic, ultrasonic or manual (palpation) guidance, for example, the physician may breach theimpermeable membrane 152 of the first impermeable membrane can 114, as shown at FIG. 27. Preferably, thefirst length 202 of theextendible portion 200 is selected so as to breach only theimpermeable membrane 152 of thefirst can 114, and not that of thesecond can 116. Preferably, the outer diameter of theextendible portion 200 is slightly smaller than the outer diameter of thecans dose escalation pen 172 to create a wide opening when breaching theimpermeable membranes 152. Similarly, thehandle portion 206 of thepen 172 should have a diameter that is slightly larger than the outer diameter of thecans extendible portion 200 within thecans dose escalation pen 172 is retracted after the impermeable membrane of thefirst can 114 is breached, afirst water path 178 is created, from the patient implant site through the first impermeable membrane can 114, through the first throughbore 122 thereof, across the firstsemipermeable membrane 120 to theosmotic engine 108. In this state of thepump 100, water may now reach theosmotic engine 108 through the initialwater access port 132 and through the first impermeable membrane can 114. - Turning now to FIGS. 29-31, when the patient requires an even greater dose of pharmaceutical agent, the physician may actuate the
actuator 192 to change the length of theextendible portion 200 to thesecond length 204, whichsecond length 204 is sufficient to penetrate thefirst can 114 and breach theimpermeable membrane 152 of the second impermeable membrane can 116, as shown at 177 FIG. 31. After thedose escalation pen 172 is retracted as shown at FIG. 31, asecond water path 180 is created. Thesecond water path 180 runs from the patient implant site through the first impermeable membrane can 114, through the breachedimpermeable membrane 152 of thesecond can 116, through the second throughbore 126 of thesecond can 116, across the secondsemipermeable membrane 124 to theosmotic engine 108. In this state of thepump 100, water may now reach theosmotic engine 108 through the initialwater access port 132, through the first impermeable membrane can 114 as well as through the second impermeable membrane can 116. - The tube-shaped
compartment 110 of thepump 100 may be pre-loaded with one or more pharmaceutical agents 30. For example, the pharmaceutical agent may be therapeutically effective for one or more of the following therapies: pain therapy, hormone therapy, gene therapy, angiogenic therapy, anti-tumor therapy, chemotherapy, allergy therapy, hypertension therapy, antibiotic therapy, bronchodilation therapy, asthmatic therapy, arrhythmia therapy, nootropic therapy, cytostatic and metastasis inhibition therapy, migraine therapy, gastrointestinal therapy and/or other pharmaceutical therapies. - For example, the pharmaceutical agent may include an opioid, a morphine-like agonist, a partial agonist, an agonist-antagonist and/or an alpha 2-adrenoreceptor agonist. Advantageously, the pharmaceutical agent may include morphine, hydromorphone, levorphanol, methadone, fentanyl, sufentanil, buprenorphine, pentazocine and/or butorphanol, for example. The pharmaceutical agent may, for example, include an analgesic agent such as Dihydrocodeine, Hydromorphone, Morphine, Diamorphine, Levorphanol, Butorphanol, Alfentanil, Pentazocine, Buprenorphine, Nefopam, Dextropropoxyphene, Flupirtine, Tramadol, Oxycodone, Metamizol, Propyphenazone, Phenazone, Nifenazone, Paracetamol, Phenylbutazone, Oxyphenbutazone, Mofebutazone, Acetyl Salicylic Acid, Diflunisal, Flurbiprofen, Ibuprofen, Diclofenac, Ketoprofen, Indomethacin, Naproxen, Meptazinol, Methadone, Pethidine, Hydrocodone, Meloxicam, Fenbufen, Mefenamic Acid, Piroxicam, Tenoxicam, Azapropazone, Codein, Bupivacaine, Ketamine, Meperidine and/or [D-Ala2,D-Leu5]enkephalin (DADL). The pharmaceutical agent may also include analgesic that is an alpha-2 adrenergetic agonist such as Clonidine, Tizadine, ST-91, Medetomidine, Dexmedetomidine and/or related alpha-2 adrenergetic agonists. The analgesic may also include an N-methyl-D-aspartate (NMDA) receptor agonist including Dexmethorphan, Ifenprodil, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801), and/or related NMDA agonists. The analgesic may also include a somatostatin analog selected including Octreotide, Sandostatin, Vapreotide, Lanreotide, and/or related Somatostatin analogs, for example. Alternatively, the pharmaceutical agent may include a non-opioid analgesic such as Ketorolac, super oxide dismutase, baclofen, calcitonin, serotonin, vasoactive intestinal polypeptide, bombesin, omega-conopeptides, and/or related non-opioid analgesics, for example. The pharmaceutical agent in the
compartment 310 may be dissolved in an aqueous solution. - For pain therapy, a preferred pharmaceutical agent is Sufentanil. In that case wherein the pharmaceutical agent is (or includes) Sufentanil that is dissolved in an aqueous medium, it has been found that the solubility of the Sufentanil within the aqueous solution increases with increasing acidity of the medium. For example, the pumps according to the present invention may be configured to deliver Sufentanil at up to about 1500 μg/day, at a concentration of up to about 500,000 μg/ml, when the Sufentanil is dissolved in an acidic aqueous medium.
- A pump according to the present invention may include a
pharmaceutical agent compartment 310 having a volume of 500 μl (microliters). Acompartment 310 of this volume may contain 500 μl of pharmaceutical agent solution, the solution including 250,000 μg of Sufentanil dissolved in an acidic aqueous medium. Therefore, about 1500 μg/day of such pharmaceutical agent solution may be delivered to the patient over a treatment period spanning about 167 days. Implanted into a patient, such a pump would deliver about 3 μl of pharmaceutical agent solution to the patient per day, each such 3 μl of pharmaceutical agent solution containing about 1500 μl of Sufentanil. - The pharmaceutical agent may also include an anti-allergic agent including Pheniramine, Dimethindene, Terfenadine, Astemizole, Tritoqualine, Loratadine, Doxylamine, Mequitazine, Dexchlorpheniramine, Triprolidine and/or Oxatomide, for example. The pharmaceutical agent may include one or more anti-hypertensive agents, such as Clonidine, Moxonidine, Methyldopa, Doxazosin, Prazosin, Urapidil, Terazosin, Minoxidil, Dihydralalzin, Deserpidine, Acebutalol, Alprenolol, Atenolol, Metoprolol, Bupranolol, Penbutolol, Propranolol, Esmolol, Bisoprolol, Ciliprolol, Sotalol, Metipranolol, Nadolol, Oxprenolol, Nifedipine, Nicardipine, Verapamil, Diltiazim, Felodipine, Nimodipine, Flunarizine, Quinapril, Lisinopril, Captopril, Ramipril, Fosinoprol and/or Enalapril, for example. Alternatively, the pharmaceutical agent may include an antibiotic agent such as Democlocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline, Sulfametopyrazine, Ofloaxcin, Ciproflaxacin, Aerosoxacin, Amoxycillin, Ampicillin, Becampicillin, Piperacillin, Pivampicillin, Cloxacillin, Penicillin V, Flucloxacillin, Erythromycin, Metronidazole, Clindamycin, Trimethoprim, Neomycin, Cefaclor, Cefadroxil, Cefixime, Cefpodoxime, Cefuroxine, Cephalexin and/or Cefradine, for example. Bronchodialotors and anti-asthmatic agents may also be pre-loaded into the tube-shaped
compartment 110, including Pirbuterol, Orciprenaline, Terbutaline, Fenoterol, Clenbuterol, Salbutamol, Procaterol, Theophylline, Cholintheophyllinate, Theophylline-ethylenediamine and/or Ketofen, for example. Anti-arrhythmic agents may also be pre-loaded into thepump 100, including Viquidil, Procainamide, Mexiletine, Tocainide, Propafenone and/or Ipratropium, for example. The pharmaceutical agent may alternatively include a centrally acting substance such as Amantadine, Levodopa, Biperiden, Benzotropine, Bromocriptine, Procyclidine, Moclobemide, Tranylcypromine, Tranylpromide, Clomipramine, Maprotiline, Doxepin, Opipramol, Amitriptyline, Desipramine, Imipramine, Fluroxamin, Fluoxetin, Paroxetine, Trazodone, Viloxazine, Fluphenazine, Perphenazine, Promethazine, Thioridazine, Triflupromazine, Prothipendyl, thiothixene, Chlorprothixene, Haloperidol, Pipamperone, Pimozide, Sulpiride, Fenethylline, Methylphenildate, Trifluoperazine, Oxazepam, Lorazepam, Bromoazepam, Alprazolam, Diazepam, Clobazam, Buspirone and/or Piracetam, for example. Cytostatics and metastasis inhibitors may also be pre-loaded within thepump 100 of the present invention, including Melfalan, Cyclophosphamide, Trofosfamide, Chlorambucil, Busulfan, Prednimustine, Fluororacil, Methotrexate, Mercaptopurine, Thioguanin, Hydroxycarbamide, Altretamine and/or Procarbazine, for example. Other pharmaceutical agents that may be pre-loaded include anti-migrane agents such as Lisuride, Methysergide, Dihydroergotamine, Ergotamine and/or Pizotifen or gastrointestinal agents such as Cimetidine, Famotidine, Ranitidine, Roxatidine, Pirenzipine, Omeprazole, Misoprostol, Proglumide, Cisapride, Bromopride and/or Metoclopramide. - The present invention is also a kit, including an implantable
osmotic pump 100, acatheter 102 configured to attach to thepump 100 and/or dose escalation pen(s) 172 configured to breach theimpermeable membranes 152 of the first and/orsecond cans - There may be instances wherein it is desired to shut the pump down. For example, an adverse reaction to the pharmaceutical agent may have occurred. FIGS. 32 and 33 are plan and perspective views, respectively, of a
membrane enclosure 112, according to embodiment of the present invention that addresses this need. As shown therein, themembrane enclosure 112 of FIGS. 32 and 33 is identical to the membrane enclosure of FIGS. 11 and 12, but for the presence of the structure referenced at 209.Reference 209 denotes an OFF switch that is configured to enable the physician to nullify or substantially nullify the osmotic pressure differential across any and all semipermeable membranes such as shown at 120 or 124. TheOFF switch 209 includes an OFF switchimpermeable membrane 210 and an OFF switchimpermeable lumen 211. When and if the OFF switchimpermeable membrane 210 is breached, fluid from the patient's implant site flows into theOFF switch lumen 211, bypasses the semipermeable membranes, and flows directly to theosmotic engine 108. Thus, any existing osmotic pressure that may have developed across such semipermeable membranes is reduced to zero or substantially zero, which correspondingly reduces the pump's driving force and reduces the delivery rate of the pharmaceutical agent to zero or about zero. The pump may then be explanted from the patient at will or may simply be left in place. - FIG. 34 is an exploded view of another embodiment of an osmotic pump according to the present invention. FIG. 34 is similar to FIG. 1, but for the
osmotic engine 108. Accordingly, the description of the structures in FIG. 1 that are identical to structures in FIG. 34 is incorporated herein by reference. In FIG. 34, at least a portion of the osmotic engine is disposed within thetube 109, at or near theproximal end 184 thereof. The tube, in this case, is preferably rigid and may be formed of, for example, stainless steel or titanium. In this manner, the expansion of theosmotic engine 108 may be entirely constrained within thetube 109, thereby pushing thepiston 162 within thetube 109 toward theproximal end 186 thereof. - FIG. 35 is an exploded view of a three-stage
osmotic pump 300, according to another embodiment of the present invention. FIG. 36 is a top view of a three stage osmotic pump according to the present invention, showing the internal structure thereof in dashed lines. FIGS. 37 and 38 are cross-sectional views of a three stage osmotic pump according to the present invention, taken along cross-sectional line BB′ and AA′ of FIG. 36. Considering now FIGS. 35-38 collectively, the constituent elements of thepump 300 that are similar to corresponding elements in FIG. 2 are identified by the same reference numerals and the detailed description thereof is omitted here. As shown, theosmotic pump 300 includes a substantially saucer-shaped housing that includes afirst housing half 302 and asecond housing half 304 that mates with thefirst housing half 302. In contradistinction to the embodiment shown in FIG. 2, theosmotic pump 300 of FIG. 35 does not include a tube, such astube 109. Instead, when mated together, the first andsecond halves tight compartment 310 that is adapted to enclose a pharmaceutical agent. Thecompartment 310 is substantially toroidal in shape, in that it resembles a tube that curves around theosmotic engine 306, following the outer curvature of the pump housing throughout most of its length. The tube-shapedcompartment 310 defines afirst end 330 that is in fluid communication with theosmotic engine 306 through apassageway 332 and asecond end 334 adjacent thecompartment outlet 314 that is formed when the first andsecond halves - The
pump 300 includes apiston 316 that is configured and adapted to travel within thecompartment 310 in response to the force exerted thereon by theosmotic engine 306. As thepiston 316 travels within thecompartment 310, it displaces a volume of pharmaceutical agent. Thepiston 316, when thepump 300 is first implanted, is located adjacent thefirst end 330 of thecompartment 310 and thereafter travels from thefirst end 330 toward thesecond end 334, displacing a volume of pharmaceutical agent as it travels. FIG. 41 shows a cross-section of an exemplary embodiment of apiston 316. As shown therein, thepiston 316 may define aleading end 322 and a trailingend 324. Additionally, to reduce the surface area of thepiston 316 that contacts the wall of thepharmaceutical agent compartment 310, the outer surface of the piston may define one ormore throughs 328 andridges 326, thereby further facilitating the travel of thepiston 316 through thecompartment 310. - Returning now to FIG. 35, the
pump 300, when configured for systemic delivery of a pharmaceutical agent (as is the case wherein the pump is implanted subcutaneously, for example), may include afilter assembly 312. Thefilter assembly 312 is configured to fit within thecompartment outlet 314, so as to maintain the substantially circular footprint of thepump 300, as shown most clearly in FIG. 36. The structure of thefilter assembly 312 is further described below, with reference to FIGS. 39 and 40. Functionally, thefilter assembly 312 filters the flow of the pharmaceutical agent from thepump 300 to the implant site within the patient or to the aqueous environment in which the pump is deployed. Thefilter assembly 312 prevents the passage of crystallized pharmaceutical agents to the patient. Crystallized pharmaceutical agents present a danger to the patient, in that the crystallized portion may contain an excess amount of agent and may cause an overdose. - Assuming that the tube-shaped
compartment 310 is substantially circular in cross-section, the volume of pharmaceutical agent that may be contained therein may be estimated by: - n/360[¼ Π2(a+b)(b−a)2
- where, as shown in FIG. 36b (which figure is not shown to the same scale as FIG. 36a), a is the inner radius of the
compartment 310, b is the outer radius of thecompartment 310 and n represents the number of degrees that thecompartment 310 is coiled around thepump 300, as shown byarrow 350. As shown in the embodiment illustrated in FIG. 36b, n is about 270°, as the portion of thecompartment 310 that is free to enclose pharmaceutical agent (i.e., from theleading edge 317 of thepiston 316 to theproximal edge 313 of the filter assembly 312) spans about ¾ of the circumference of thepump 300. - The
pump 300 may also include aring 308. Thering 308 is preferably formed of the same material as the first andsecond housing halves pump 300, thepiston 316 may be placed adjacent thefirst end 330 of thecompartment 310 and theosmotic engine 306 may be centered between the first andsecond housing halves second housing halves impermeable membrane cans ring 308 may then be inserted into the central opening formed by the first andsecond housing halves semipermeable membrane enclosure 112, complete with the first and secondimpermeable cans ring 308, taking care to align the first throughbore 124 with the first semipermeable membrane well 146 and the second throughbore 124 with the secondsemipermeable membrane well 148. Theenclosure 112 may then be welded to thering 308 and thering 308 may be welded to thefirst half 302 of the pump housing (not necessarily in that order). Thecompartment 310 may then be filled with pharmaceutical agent (not shown in FIG. 35) and thefilter assembly 312 may thereafter be fitted within thecompartment outlet 314 and secured therein. Note that the initial dose semipermeable membrane fitted within the initial dose semipermeable membrane well 336 is not shown in FIGS. 35-38, nor is the first semipermeable membrane fitted within the first semipermeable membrane well 146 or the second semipermeable membrane fitted within the secondsemipermeable membrane well 148. Themembrane enclosure 112 may also incorporate the OFF switch features shown in FIGS. 32 and 33. According to the embodiment of the present invention shown in FIGS. 35-38, thepump 300 is adapted to deliver a pharmaceutical agent or agents at three distinct rates. The first or initial rate occurs when thepump 300 is implanted within the patient and only the initialwater access port 130 is in fluid communication with the fluid environment of the pump's implant site within the patient. In this configuration, water from the implant site enters the pump at 130, crosses the initial dose semipermeable membrane in the semipermeable membrane well 336 and comes into contact with theosmotic engine 306, causing theengine 306 to swell and to push thepiston 316 toward thesecond end 334 of thecompartment 310 at an initial first rate. Thereafter, the physician may puncture the impermeable membrane of thefirst can 114, thereby causing water form the implant site to enter therein, cross the first semipermeable membrane within the first semipermeable membrane well 146 and reach theosmotic engine 306. The delivery rate of thepump 300 is now increased from its first, initial rate to a second, larger rate, as more water from the patient implant site is reaching theosmotic engine 306, causing it to swell at a faster rate, thereby causing topiston 316 to travels within thecompartment 310 at a corresponding second, faster rate. When the second impermeable membrane can 116 is breached, water from the implant site enters therein, crosses the second semipermeable membrane within the second semipermeable membrane well 148 and reaches theosmotic engine 306. The delivery rate of thepump 300 is now increased from its second rate to a third, even greater rate, as more water from the patient implant site reaches theosmotic engine 306, causing it to swell at a faster rate, thereby causing topiston 316 to travel within thecompartment 310 at a third, faster rate, thus displacing a greater amount of pharmaceutical agent than either the initial or second rates. - FIG. 39 is a cross-sectional view of the
filter assembly 312 of FIG. 35 and FIG. 40 is a front view of thefilter assembly 312 of FIG. 35. As shown in FIGS. 35 and 39-40, thefilter assembly 312 may be (but need not be) shaped as a slanted and truncated circular cylinder. Thefilter assembly 312 defines aproximal end 313 and adistal end 315. Theassembly 312 further defines apharmaceutical agent inlet 321 that emerges at theproximal end 313 and apharmaceutical agent outlet 320 that emerges at the distal end of thefilter assembly 312. Between theinlet 321 and theoutlet 320, the filter assembly includes afilter 318. According to the present invention, thefilter 318 may include a plug of porous material that defines a plurality of pores. The pores, according to an embodiment of the present invention, may range from about 2 microns in average pore size to about 80 microns in average pore size, for example. For example, the average pore size of the porous material of thefilter 318 may be selected within the range of about 5 microns to about 20 microns. - The porous material of the
filter 318 may be selected to be hydrophilic or hydrophobic, depending upon, for example, the nature of the pharmaceutical agent contained in thepump 300. The pharmaceutical agent in thecompartment 310 may be dissolved in an aqueous solution. Alternatively, the pharmaceutical agent in thecompartment 310 of thepump 300 may be dissolved in a non-aqueous solution, such as alcohol (benzyl alcohol, for example). In such a case, thefilter assembly 318 may include a filter that is substantially hydrophobic in nature, which would allow the passage of a hydrophobic solution, but would not admit the passage of a (or a substantial amount of a hydrophilic solution such as water. Water (or substantial amounts thereof) from the patient implant site, therefore, could not get into thepump 300 and only the pharmaceutical agent could get out, into the patient. Alternatively, theporous material 318 may have hydrophilic characteristics. When theporous material 318 of thefilter assembly 312 is hydrophilic, reliance is made on the pressure differential across the porous material 318 (higher on theproximal end 313 than on thedistal end 315 end thereof, due to the pressure exerted by the osmotic engine 306) as well as on the pore size of theporous material 318 to limit the diffusion into thepump 300. The pore size may be selected depending upon the magnitude of the pressure differential across thefilter assembly 312, the length of thefilter 318, the nature of the pharmaceutical agent to be delivered (for example, some pharmaceutical agent including large-sized protein molecules such contained in many pain medications may require afilter 318 defining relatively large size pores) and the aspect ratio of the filter 318 (ratio of aggregate pore size to length of filter 318), among other factors. Suitable materials for the porous material of thefilter 318 may be obtained from, for example Millipore Corp. (http://www.millipore.com), Porex Corp. (http//:www.porex.com) and others. - FIGS. 42, 43 and44 show a perspective view, an exploded view and a top view of a single stage osmotic pump according to another embodiment of the present invention, with the top view of FIG. 44 showing internal components thereof in dashed lines. The
pump 400 includes first andsecond housing halves filter assembly 312,piston 316,osmotic engine 306 andring 308, each of which being similar or identical to those structures in FIGS. 35-38 referenced by the same numerals. A detailed description of these structures is, therefore, omitted here. The single-stage pump 400 may include asemipermeable membrane enclosure 412. Thesemipermeable membrane enclosure 412 may define awater access port 430 through which water from the patient implant site enters thepump 400. Theenclosure 412 also defines awater outlet port 438, thorough which water comes into contact with theosmotic engine 306. Between thewater inlet port 430 and thewater outlet port 438 is disposed a semipermeable membrane. Thewater inlet port 430 may be covered by an impermeable membrane of stainless steel or titanium, for example. Moreover, a saturated saline solution may be present between the impermeable membrane covering thewater inlet port 430 and the semipermeable membrane within theenclosure 412. Such a saturated saline solution maintains the semipermeable membrane in a hydrated state, and speeds up the initial delivery of the pharmaceutical agent contained in thecompartment 310 of thepump 400 once the (optional) impermeable membrane covering thewater inlet port 430 is breached. Such an impermeable membrane would be included in thepump 400 only if it was desired to implant thepump 400 in an inactive state and, at some later time, activate it so as to initiate the delivery of the pharmaceutical agent contained therein. Thesingle stage pump 400 may also include the OFF switch features shown in FIGS. 32 and 33. - The pharmaceutical agent compartment of the pumps according to the present invention, as noted above, may contain sufentanil, for example, and may also contain other medications. Depending upon the clinical indication, the pumps according to the present invention may be configured for intravascular, subcutaneous, epidural, intrathecal or intraventricular use. Table 1 below details exemplary maximum expected dosages of Sufentanil for above-listed uses.
TABLE 1 Expected Maximum Dosage of Sufentanil (μg/day) Intravascular 1500 Subcutaneous 1500 Epidural 500 Intrathecal 50 Intraventricular 25 - Table 2 below shows exemplary delivery schedules for pumps according to the present invention having a diameter of 1.8 cm and a
compartment 310 having a capacity of 200 mg, a diameter of 2.8 cm and acompartment 310 having a capacity of 500 mg and a diameter of 5.0 cm and acompartment 310 having a capacity of 2000 mg over selected delivery rates (in mg/day) ranging from 0.50 mg/day to 20.0 mg/day.Exemplary Delivery Schedule Months of Delivery 1.8 cm diameter 2.8 cm diameter 5.0 cm diameter Delivery Rate 200 mg capacity 500 mg capacity 2000 mg capacity (mg/day) (Without dose escalation) (With dose escalation) (With dose escalation) 0.50 12 — — 0.75 8 12 — 2.00 3.3 6 — 5.00 — 3.3 12 10.0 — — 6 20.0 — — 3.3 - The present invention may be implanted under the patient's skin in an outpatient setting. The implantation procedure may be performed with a local anesthetic and may be carried out in as little as 15-20 minutes, for example. Depending upon the implant site, a small 0.5 to 0.75 inch incision may be all that is required, which incision may later be closed with one or more STERI-STRIP® skin closure devices or sutures, for example. The thin, circular shape of the pumps according to the present invention facilitates placement thereof in a number of locations throughout the patient's body, including the chest wall, the lower back, the arms and legs, the neck and even under the scalp, to identify a few exemplary locations. It is to be understood, however, that the above list of possible implant sites is not to be construed as limiting the locations at which the present pumps may be implanted, as those of skill in this art may recognize. The present invention has been presented within the context of pain management and of drugs of a potency comparable to Sufentanil. However, the present invention may be scaled appropriately to deliver any volume of drug at any potency level.
- While the foregoing detailed description has described preferred embodiments of the present invention, it is to be understood that the above description is illustrative only and not limiting of the disclosed invention. Those of skill in this art will recognize other alternative embodiments and all such embodiments are deemed to fall within the scope of the present invention. Thus, the present invention should be limited only by the claims as set forth below.
Claims (43)
1. An implantable osmotic pump for delivering a pharmaceutical agent to a patient, comprising:
a catheter;
an osmotic engine;
a pharmaceutical agent compartment;
a volume of pharmaceutical agent that includes Sufentanil within the pharmaceutical agent compartment, and
a piston disposed within the compartment, the compartment being configured such that the osmotic engine causes the piston to travel within the compartment along an arcuate path and deliver the pharmaceutical agent through the catheter when the pump is implanted in the patient, wherein the pump is configured for:
a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the catheter is placed intraventricularly;
a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the catheter is placed intrathecally;
a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the catheter is placed epidurally;
a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the catheter is placed subcutaneously, and
a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the catheter is placed intravascularly.
2. The pump of claim 1 , wherein the compartment is disposed at least partially around the osmotic engine.
3. The pump of claim 1 , wherein the osmotic engine includes a base, a cylindrical wall attached to the base and a free end opposite the base.
4. The pump of claim 1 , further including a housing configured to enclose at least the osmotic engine and the compartment.
5. The pump of claim 4 , wherein the housing includes a first housing half and a second housing half that mates with the first housing half.
6. The pump of claim 5 , wherein each of the first and second housing halves define a saucer shape.
7. The pump of claim 5 , wherein each of the first and the second housing halves are substantially circular in shape.
8. The pump of claim 5 , wherein the first housing half defines a substantially circular opening.
9. The pump of claim 1 , further including a membrane enclosure, the membrane enclosure being partially surrounded by the osmotic engine and including an initial dose semipermeable membrane that is configured to allow water from the patient to reach the osmotic engine when the pump is implanted.
10. The pump of claim 9 , wherein the pump is configured to deliver an initial dose of the pharmaceutical agent to the patient at a selected initial infusion rate, the selected initial infusion rate being related to at least one of a thickness, a composition and a surface area of the initial dose semipermeable membrane.
11. The pump of claim 9 , wherein the initial dose semipermeable membrane is fitted with an initial dose impermeable membrane that initially seals the initial dose semipermeable membrane.
12. The pump of claim 11 , further including a volume of a saturated saline solution between the initial dose semipermeable membrane and the initial dose semipermeable membrane.
13. The pump of claim 9 , further including a dose escalation assembly fitted in the membrane enclosure, the dose escalation assembly being adapted to selectively increase an amount of water from the patient that reaches the osmotic engine when the pump is implanted.
14. The pump of claim 13 , wherein the dose escalation assembly includes a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached.
15. The pump of claim 13 , wherein the dose escalation assembly includes:
a first impermeable membrane configured to enable water from the patient to reach the osmotic engine through a first fluid path only after being breached, and
a second impermeable membrane configured to enable water from the patient to reach the osmotic engine through a second fluid path only after being breached, the first path being distinct from the second path.
16. The pump of claim 15 , wherein the first and second impermeable membranes are disposed in the membrane enclosure in a stacked configuration wherein the first impermeable membrane must be breached before the second impermeable membrane can be breached.
17. The pump of claim 15 , wherein the first fluid path includes a first semipermeable membrane and wherein the second fluid path includes a second semipermeable membrane that is distinct from the first semipermeable membrane.
18. The pump of claim 17 , wherein the pump is configured to deliver a first dose of the pharmaceutical agent to the patient at a selected first infusion rate and a second dose of the pharmaceutical agent to the patient at a selected second infusion rate that is greater than the first infusion rate, the selected first and second infusion rates being related to at least one of a thickness, a composition and a surface area of the first and second semipermeable membranes, respectively.
19. The pump of claim 1 , wherein the osmotic engine includes a hygroscopic salt.
20. The pump of claim 1 , wherein the osmotic engine includes an absorbent polymer.
21. The pump of claim 20 , wherein the absorbent polymer includes a material selected from a group including poly(acrylic acid), potassium salt; poly(acrylic acid), sodium salt; poly(acrylic acid-co-acrylamide), potassium salt; poly(acrylic acid), sodium salt-graft-poly(ethylene oxide); poly (2-hydroxethyl methacrylate); poly(2-hydroxypropyl methacrylate) and poly(isobutylene-co-maleic acid) or derivatives thereof.
22. The pump of claim 1 , wherein the compartment has a substantially constant inner diameter over a length thereof.
23. The pump of claim 1 , wherein the compartment has a non-constant inner diameter over a length thereof.
24. The pump of claim 1 , wherein the catheter includes a radiopaque tip.
25. The pump of claim 1 , wherein the piston includes one of a sphere, an elastomeric cylinder and an elastomeric conical section.
26. The pump of claim 25 , wherein the piston includes at least one of stainless steel, a refractory metal, plastic, nylon and rubber.
27. The pump of claim 1 , wherein the sufentanil is at a concentration up to about 500,000 μg/mL.
28. The pump of claim 13 , wherein the dose escalation assembly includes:
a first saturated saline solution between the first impermeable membrane and the first semipermeable membrane, and
a second saturated saline solution between the second impermeable membrane and the second semipermeable membrane.
29. A method of delivering a pharmaceutical agent to a patient, comprising steps of:
implanting a pump into the patient, the pump including a pump engine and a compartment adapted to store a pharmaceutical agent, and
causing a piston to travel a distance within the compartment along an arcuate path and to deliver a dose of pharmaceutical agent out of the compartment.
30. The method of claim 29 , wherein the implanting step is carried such that the pharmaceutical agent is delivered one of intravascularly, subcutaneously, epidurally, intrathecally and intraventricularly.
31. The method of claim 30 , wherein the pharmaceutical agent includes Sufentanil and wherein the pump is configured for:
a daily delivery rate of Sufentanil of up to about 125 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intraventricularly;
a daily delivery rate of Sufentanil of up to about 250 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intrathecally;
a daily delivery rate of Sufentanil of up to about 750 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered epidurally;
a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered subcutaneously, and
a daily delivery rate of Sufentanil of up to about 1500 micrograms per day when the implanting step is carried out such that the pharmaceutical agent is delivered intravascularly.
32. The method of claim 30 , wherein travel of the piston within the compartment causes a delivery of a volume up to about 20 μL/day over a treatment period.
33. The method of claim 29 , further comprising the step of selectively increasing the dose in a stepwise manner over a treatment period without removing the pump from the patient.
34. The method of claim 33 , wherein the pump engine includes an osmotic engine and wherein the pump includes an initial dose semipermeable membrane initially exposed to the patient and at least one second semipermeable membrane initially not exposed to the patient and wherein the increasing step includes a step of selectively exposing the at least one second semipermeable membrane to the patient.
35. The method of claim 29 , wherein the pump the engine includes an osmotic engine in fluid communication with the piston and wherein the causing step includes a step of increasing a volume of the osmotic engine.
36. A pump, comprising:
a pump engine;
a compartment adapted to store a fluid, the compartment being disposed at least partially around the pump engine, and
a piston disposed within the compartment, the compartment and the engine being configured to cause the piston to travel within the compartment along an arcuate path and to force a volume of the fluid out of the pump.
37. The pump of claim 36 , wherein the pump engine includes an osmotic engine.
38. The pump of claim 36 , wherein the fluid includes a pharmaceutical agent.
39. The pump of claim 36 , further including a catheter coupled to the compartment.
40. The pump of claim 36 , wherein the pump is fully implantable in a body and wherein pump engine and the compartment are enclosed in a biocompatible pump housing.
41. The pump of claim 36 , further including a dose escalation assembly, the escalation assembly being configured to selectively increase the dose of fluid delivered.
42. The pump of claim 36 , wherein the dose escalation assembly comprises means for increasing the dose delivered in a stepwise manner.
43. The pump of claim 36 , wherein the piston includes one of a sphere, an elastomeric cylinder and an elastomeric conical section.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/685,291 US20040249365A1 (en) | 2001-04-19 | 2003-10-14 | Implantable osmotic pump |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/838,662 US6632217B2 (en) | 2001-04-19 | 2001-04-19 | Implantable osmotic pump |
US10/685,291 US20040249365A1 (en) | 2001-04-19 | 2003-10-14 | Implantable osmotic pump |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/838,662 Continuation US6632217B2 (en) | 2001-04-19 | 2001-04-19 | Implantable osmotic pump |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040249365A1 true US20040249365A1 (en) | 2004-12-09 |
Family
ID=25277746
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/838,662 Expired - Fee Related US6632217B2 (en) | 2001-04-19 | 2001-04-19 | Implantable osmotic pump |
US10/346,575 Abandoned US20030135202A1 (en) | 2001-04-19 | 2003-01-17 | Implantable osmotic pump |
US10/685,291 Abandoned US20040249365A1 (en) | 2001-04-19 | 2003-10-14 | Implantable osmotic pump |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/838,662 Expired - Fee Related US6632217B2 (en) | 2001-04-19 | 2001-04-19 | Implantable osmotic pump |
US10/346,575 Abandoned US20030135202A1 (en) | 2001-04-19 | 2003-01-17 | Implantable osmotic pump |
Country Status (3)
Country | Link |
---|---|
US (3) | US6632217B2 (en) |
AU (1) | AU2002307085A1 (en) |
WO (1) | WO2002085428A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007011923A2 (en) * | 2005-07-15 | 2007-01-25 | Microlin, Llc | Fluid delivery device |
US20080147186A1 (en) * | 2006-12-14 | 2008-06-19 | Joshi Ashok V | Electrochemical Implant For Delivering Beneficial Agents |
US20120288551A1 (en) * | 2011-05-10 | 2012-11-15 | Antecip Bioventures Ii Llc | Implantable Polymeric Device for Sustained Release of Sufentanil |
US9616207B2 (en) | 2014-06-26 | 2017-04-11 | Cochlear Limited | Treatment of the ear |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
DE10053397A1 (en) | 2000-10-20 | 2002-05-02 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
DE10066158B4 (en) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome |
DE10064453A1 (en) * | 2000-12-16 | 2002-07-04 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
US20030181426A1 (en) * | 2002-02-11 | 2003-09-25 | Eisenach James C. | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
US6864271B2 (en) * | 2002-11-12 | 2005-03-08 | The Foundation For The Lsu Health Sciences Center | Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives |
US20050038415A1 (en) * | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
GB0320297D0 (en) * | 2003-08-29 | 2003-10-01 | Univ Warwick | Blood pressure monitor |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US8708993B1 (en) * | 2003-10-15 | 2014-04-29 | Physician Technologies, Inc. | Infusion catheter procedure and system |
US20050180974A1 (en) * | 2003-10-24 | 2005-08-18 | Medtronic, Inc. | Extracellular TNF inhibitors for treating CNS disorders |
US20050240166A1 (en) * | 2004-04-26 | 2005-10-27 | Microsolutions, Inc. | Implantable device, formulation and method for anti-psychotic therapy using risperidone |
US7824697B2 (en) | 2004-07-12 | 2010-11-02 | Board Of Regents, The University Of Texas System | High concentration baclofen preparations |
DE102004042578A1 (en) * | 2004-09-02 | 2006-03-23 | Roche Diagnostics Gmbh | Micropump for pumping liquids with low flow rates in pressure / suction operation |
US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
WO2006079055A2 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US8202259B2 (en) | 2005-03-04 | 2012-06-19 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
EP1858565B1 (en) | 2005-03-04 | 2021-08-11 | C.R. Bard, Inc. | Access port identification systems and methods |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
EP1874393B1 (en) | 2005-04-27 | 2017-09-06 | C.R.Bard, Inc. | Infusion apparatuses |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
EP2324878B1 (en) | 2005-04-27 | 2014-08-20 | C.R. Bard, Inc. | Infusion apparatuses provided with septum |
US20060280655A1 (en) * | 2005-06-08 | 2006-12-14 | California Institute Of Technology | Intravascular diagnostic and therapeutic sampling device |
US9447781B2 (en) * | 2005-07-22 | 2016-09-20 | University Of Utah Research Foundation | Osmotically driven dispense pump and related components for use in high pressure applications |
US8801694B2 (en) | 2005-08-11 | 2014-08-12 | Massachusetts Institute Of Technology | Intravesical drug delivery device |
US20070087055A1 (en) * | 2005-10-14 | 2007-04-19 | David Jan | Directly compressible extended release alprazolam formulation |
US7874998B2 (en) | 2005-11-04 | 2011-01-25 | The Regents Of The University Of Michigan | Filtration devices and related methods thereof |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US8267905B2 (en) * | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
CN101453982B (en) * | 2006-05-30 | 2011-05-04 | 精达制药公司 | Two-piece, internal-channel osmotic delivery system flow modulator |
US7803148B2 (en) | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
US20090198183A1 (en) * | 2006-11-03 | 2009-08-06 | Krumme John F | Apparatus and methods for injecting dermal fillers |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
RU2440097C2 (en) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it |
MX2009014100A (en) | 2007-06-20 | 2010-09-14 | Medical Components Inc | Venous access port with molded and/or radiopaque indicia. |
WO2009012395A1 (en) | 2007-07-19 | 2009-01-22 | Innovative Medical Devices, Llc | Venous access port assembly with x-ray discernable indicia |
EP3311877A1 (en) | 2007-07-19 | 2018-04-25 | Medical Components, Inc. | Venous access port assembly with x-ray discernable indicia |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
GB2446247B (en) * | 2007-11-27 | 2008-12-17 | Robert Joseph Wagener | Homeostatic insulin pump |
US20090209945A1 (en) * | 2008-01-18 | 2009-08-20 | Neurosystec Corporation | Valveless impedance pump drug delivery systems |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20150258279A1 (en) | 2008-03-18 | 2015-09-17 | Mallinckrodt Llc | Intrathecal baclofen pharmaceutical dosage forms and related delivery system |
US8969414B2 (en) | 2009-02-06 | 2015-03-03 | Mallinckrodt Llc | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products |
CN101977643A (en) * | 2008-03-24 | 2011-02-16 | 奥林巴斯株式会社 | Medicinal-solution administration device |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
BRPI0917135A2 (en) * | 2008-08-09 | 2015-11-10 | Massachusetts Inst Technology | medical device for extension and retention in a patient's seminal vesicle, ejaculatory duct, prostate or vas deferens, use of a resorbable elastomer, and osmotic pump device. |
EP2158927A1 (en) * | 2008-08-25 | 2010-03-03 | Debiotech S.A. | Drug delivery device with a module for preventing fibrillation downstream of its reservoir |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2010144016A1 (en) | 2009-06-09 | 2010-12-16 | Neuronano Ab | Microelectrode and multiple microelectrodes comprising means for releasing drugs into the tissue |
EA023156B1 (en) | 2009-06-26 | 2016-04-29 | ТАРИС Биомедикал ЛЛК | Drug delivery device |
US8715244B2 (en) | 2009-07-07 | 2014-05-06 | C. R. Bard, Inc. | Extensible internal bolster for a medical device |
US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
ES2695907T3 (en) | 2009-11-17 | 2019-01-11 | Bard Inc C R | Overmolded access port that includes anchoring and identification features |
US8716350B2 (en) | 2010-03-30 | 2014-05-06 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
EP2552433A4 (en) | 2010-03-30 | 2013-11-06 | Algynomics Inc | Compositions and methods for the treatment of somatosensory disorders |
US20110251568A1 (en) * | 2010-04-08 | 2011-10-13 | Beeley Nathan R F | Punctal plugs for controlled release of therapeutic agents |
HUE051942T2 (en) | 2010-08-05 | 2021-03-29 | Taris Biomedical Llc | Implantable drug delivery devices for genitourinary sites |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2694120A1 (en) | 2011-04-07 | 2014-02-12 | Allergan, Inc. | Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture |
TWI615155B (en) * | 2011-11-01 | 2018-02-21 | 拜耳股份有限公司 | Osmotically active vaginal delivery system |
US10213533B2 (en) * | 2012-03-05 | 2019-02-26 | Keith A. Walter | Medical tools with aspiration tips suitable for cataract surgeries and related methods |
US9404580B2 (en) * | 2012-04-13 | 2016-08-02 | United Technologies Corporation | Duplex finger seal for joints with high relative displacement |
EP2852595B1 (en) | 2012-05-21 | 2016-06-22 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
US10220186B2 (en) | 2012-05-23 | 2019-03-05 | Becton, Dickinson And Company | Collapse-resistant swellable catheter |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
TW201412740A (en) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | Substituted pyrrolopyrimidinylamino-benzothiazolones |
JP5683620B2 (en) * | 2013-02-26 | 2015-03-11 | プライムテック株式会社 | Fluid transport device |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
CN105163794B (en) | 2013-03-15 | 2020-03-27 | 塔里斯生物医药公司 | Drug delivery device and method with drug permeable member |
EP4234036A3 (en) | 2013-08-19 | 2023-11-01 | TARIS Biomedical LLC | Multi-unit drug delivery devices |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US9579289B2 (en) | 2015-02-20 | 2017-02-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
EP3285850A1 (en) | 2015-04-23 | 2018-02-28 | TARIS Biomedical LLC | Drug delivery devices with drug-permeable component and methods |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
KR20220008824A (en) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | How to treat anxiety disorders, headache disorders and eating disorders with psilocybin |
Citations (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4031891A (en) * | 1975-11-03 | 1977-06-28 | Baxter Travenol Laboratories, Inc. | Air eliminating filter |
US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4058122A (en) * | 1976-02-02 | 1977-11-15 | Alza Corporation | Osmotic system with laminated wall formed of different materials |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4093708A (en) * | 1974-12-23 | 1978-06-06 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4193398A (en) * | 1978-05-25 | 1980-03-18 | Watson-Marlow Limited | Fluid displacement |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4203439A (en) * | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4278087A (en) * | 1980-04-28 | 1981-07-14 | Alza Corporation | Device with integrated operations for controlling release of agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4298003A (en) * | 1980-05-12 | 1981-11-03 | Alza Corporation | System for delivering agent at zero order rate with emerging agent below saturation |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4379203A (en) * | 1980-05-23 | 1983-04-05 | Siemens Aktiengesellschaft | Housing for laser apparatus |
US4410328A (en) * | 1981-07-10 | 1983-10-18 | Alza Corporation | Dispensing device with internal drive |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US4455145A (en) * | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4503030A (en) * | 1983-06-06 | 1985-03-05 | Alza Corporation | Device for delivering drug to certain pH environments |
US4552561A (en) * | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
US4587117A (en) * | 1983-06-06 | 1986-05-06 | Alza Corporation | Medical device for delivering drug to pH environments greater than 3.5 |
US4608046A (en) * | 1977-08-19 | 1986-08-26 | Keivan Towfigh | Flat folded female urinary aid |
US4610686A (en) * | 1983-11-02 | 1986-09-09 | Alza Corporation | Controlled delivery of haloperidol by an osmotic delivery system |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
US4619652A (en) * | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4655766A (en) * | 1985-08-01 | 1987-04-07 | Alza Corporation | Fluid imbibing pump with self-regulating skin patch |
US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4685918A (en) * | 1985-02-01 | 1987-08-11 | Merck & Co., Inc. | Lipid osmotic pump |
US4705515A (en) * | 1984-10-26 | 1987-11-10 | Alza Corporation | Dosage form for administering drug of the colon |
US4711251A (en) * | 1980-09-02 | 1987-12-08 | Medtronic, Inc. | Body implantable lead |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4732915A (en) * | 1983-11-02 | 1988-03-22 | Alza Corporation | Process for increasing solubility of drug |
US4751071A (en) * | 1983-12-01 | 1988-06-14 | Alza Corporation | Composition comprising salbutamol |
US4756314A (en) * | 1985-10-28 | 1988-07-12 | Alza Corporation | Sweat collection patch |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4783413A (en) * | 1986-07-30 | 1988-11-08 | Contraves Ag | Apparatus for supplying a medium to a reaction chamber |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US4880631A (en) * | 1987-09-24 | 1989-11-14 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4898582A (en) * | 1988-08-09 | 1990-02-06 | Pharmetrix Corporation | Portable infusion device assembly |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5257987A (en) * | 1990-05-21 | 1993-11-02 | Pharmetrix Corporation | Controlled release osmotic infusion system |
US5279608A (en) * | 1990-12-18 | 1994-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Osmotic pumps |
US5318540A (en) * | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5492534A (en) * | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
US5562654A (en) * | 1994-10-28 | 1996-10-08 | University Of Kentucky Research Foundation | Time-released delivery system |
US5607696A (en) * | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
US5672168A (en) * | 1994-10-07 | 1997-09-30 | De La Torre; Roger A. | Laparoscopic access port for surgical instruments or the hand |
US5728396A (en) * | 1996-02-02 | 1998-03-17 | Alza Corporation | Sustained delivery of leuprolide using an implantable system |
US5752930A (en) * | 1995-04-28 | 1998-05-19 | Medtronic, Inc. | Implantable techniques for infusing equal volumes of agents to spaced sites |
US5795591A (en) * | 1991-10-10 | 1998-08-18 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5798119A (en) * | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
US5801188A (en) * | 1997-01-08 | 1998-09-01 | Medtronic Inc. | Clonidine therapy enhancement |
US5827538A (en) * | 1993-07-22 | 1998-10-27 | Pfizer Inc. | Osmotic devices having vapor-permeable coatings |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5869096A (en) * | 1989-07-14 | 1999-02-09 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US5876752A (en) * | 1990-08-07 | 1999-03-02 | Pfizer Inc. | Use of interfacially-polymerized membranes in delivery devices |
US5904934A (en) * | 1993-06-23 | 1999-05-18 | Alza Corporation | Ruminal drug delivery device |
US5980509A (en) * | 1988-12-13 | 1999-11-09 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US6117125A (en) * | 1996-05-02 | 2000-09-12 | Cook Incorporated | Method for predetermining uniform flow rate of a fluid from a tubular body and device therefrom |
US6582418B1 (en) * | 2000-06-01 | 2003-06-24 | Medtronic, Inc. | Drug pump with reinforcing grooves |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4487803A (en) * | 1982-02-02 | 1984-12-11 | United States Borax & Chemical Corporation | Boric acid having improved handling properties |
US4608048A (en) | 1984-12-06 | 1986-08-26 | Alza Corporation | Dispensing device with drug delivery patterns |
US5499979A (en) * | 1987-06-25 | 1996-03-19 | Alza Corporation | Delivery system comprising kinetic forces |
US4886668A (en) | 1987-09-24 | 1989-12-12 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic pump |
US4976966A (en) | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
US5273752A (en) | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5169390A (en) | 1990-05-21 | 1992-12-08 | Athayde Amulya L | Osmotic infusion device |
US5672167A (en) | 1990-05-21 | 1997-09-30 | Recordati Corporation | Controlled release osmotic pump |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
US6283949B1 (en) * | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6752930B2 (en) * | 2001-05-18 | 2004-06-22 | Peter L. Alexander | Chlorination apparatus and method |
-
2001
- 2001-04-19 US US09/838,662 patent/US6632217B2/en not_active Expired - Fee Related
-
2002
- 2002-04-03 WO PCT/US2002/010425 patent/WO2002085428A2/en not_active Application Discontinuation
- 2002-04-03 AU AU2002307085A patent/AU2002307085A1/en not_active Abandoned
-
2003
- 2003-01-17 US US10/346,575 patent/US20030135202A1/en not_active Abandoned
- 2003-10-14 US US10/685,291 patent/US20040249365A1/en not_active Abandoned
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4135514A (en) * | 1974-12-23 | 1979-01-23 | Alza Corporation | Osmotic releasing system for administering ophthalmic drug to eye of animal |
US4096238A (en) * | 1974-12-23 | 1978-06-20 | Alza Corporation | Method for administering drug to the gastrointestinal tract |
US4093708A (en) * | 1974-12-23 | 1978-06-06 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US4142526A (en) * | 1974-12-23 | 1979-03-06 | Alza Corporation | Osmotic releasing system with means for changing release therefrom |
US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4031891A (en) * | 1975-11-03 | 1977-06-28 | Baxter Travenol Laboratories, Inc. | Air eliminating filter |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4160020A (en) * | 1975-11-24 | 1979-07-03 | Alza Corporation | Therapeutic device for osmotically dosing at controlled rate |
US4058122A (en) * | 1976-02-02 | 1977-11-15 | Alza Corporation | Osmotic system with laminated wall formed of different materials |
US4116241A (en) * | 1976-02-02 | 1978-09-26 | Alza Corporation | Osmotic system with laminated wall comprising structurally different semipermeable lamina |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4203439A (en) * | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4608046A (en) * | 1977-08-19 | 1986-08-26 | Keivan Towfigh | Flat folded female urinary aid |
US4193398A (en) * | 1978-05-25 | 1980-03-18 | Watson-Marlow Limited | Fluid displacement |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4278087A (en) * | 1980-04-28 | 1981-07-14 | Alza Corporation | Device with integrated operations for controlling release of agent |
US4298003A (en) * | 1980-05-12 | 1981-11-03 | Alza Corporation | System for delivering agent at zero order rate with emerging agent below saturation |
US4379203A (en) * | 1980-05-23 | 1983-04-05 | Siemens Aktiengesellschaft | Housing for laser apparatus |
US4711251A (en) * | 1980-09-02 | 1987-12-08 | Medtronic, Inc. | Body implantable lead |
US4711251B1 (en) * | 1980-09-02 | 1994-06-28 | Medtronic Inc | Body implantable lead |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4410328A (en) * | 1981-07-10 | 1983-10-18 | Alza Corporation | Dispensing device with internal drive |
US4455145A (en) * | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
US4619652A (en) * | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
US4552561A (en) * | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4587117A (en) * | 1983-06-06 | 1986-05-06 | Alza Corporation | Medical device for delivering drug to pH environments greater than 3.5 |
US4503030A (en) * | 1983-06-06 | 1985-03-05 | Alza Corporation | Device for delivering drug to certain pH environments |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4610686A (en) * | 1983-11-02 | 1986-09-09 | Alza Corporation | Controlled delivery of haloperidol by an osmotic delivery system |
US4732915A (en) * | 1983-11-02 | 1988-03-22 | Alza Corporation | Process for increasing solubility of drug |
US4751071A (en) * | 1983-12-01 | 1988-06-14 | Alza Corporation | Composition comprising salbutamol |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4705515A (en) * | 1984-10-26 | 1987-11-10 | Alza Corporation | Dosage form for administering drug of the colon |
US4685918A (en) * | 1985-02-01 | 1987-08-11 | Merck & Co., Inc. | Lipid osmotic pump |
US4655766A (en) * | 1985-08-01 | 1987-04-07 | Alza Corporation | Fluid imbibing pump with self-regulating skin patch |
US4756314A (en) * | 1985-10-28 | 1988-07-12 | Alza Corporation | Sweat collection patch |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4783413A (en) * | 1986-07-30 | 1988-11-08 | Contraves Ag | Apparatus for supplying a medium to a reaction chamber |
US4880631A (en) * | 1987-09-24 | 1989-11-14 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
US4898582A (en) * | 1988-08-09 | 1990-02-06 | Pharmetrix Corporation | Portable infusion device assembly |
US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
US5980509A (en) * | 1988-12-13 | 1999-11-09 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5869096A (en) * | 1989-07-14 | 1999-02-09 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5318540A (en) * | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5413572A (en) * | 1990-04-02 | 1995-05-09 | Alza Corporation | Osmotic dosage system for liquid drug delivery |
US5492534A (en) * | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
US5257987A (en) * | 1990-05-21 | 1993-11-02 | Pharmetrix Corporation | Controlled release osmotic infusion system |
US5876752A (en) * | 1990-08-07 | 1999-03-02 | Pfizer Inc. | Use of interfacially-polymerized membranes in delivery devices |
US5312389A (en) * | 1990-10-29 | 1994-05-17 | Felix Theeuwes | Osmotically driven syringe with programmable agent delivery |
US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5279608A (en) * | 1990-12-18 | 1994-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Osmotic pumps |
US5795591A (en) * | 1991-10-10 | 1998-08-18 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5904934A (en) * | 1993-06-23 | 1999-05-18 | Alza Corporation | Ruminal drug delivery device |
US5827538A (en) * | 1993-07-22 | 1998-10-27 | Pfizer Inc. | Osmotic devices having vapor-permeable coatings |
US5672168A (en) * | 1994-10-07 | 1997-09-30 | De La Torre; Roger A. | Laparoscopic access port for surgical instruments or the hand |
US5562654A (en) * | 1994-10-28 | 1996-10-08 | University Of Kentucky Research Foundation | Time-released delivery system |
US5607696A (en) * | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5752930A (en) * | 1995-04-28 | 1998-05-19 | Medtronic, Inc. | Implantable techniques for infusing equal volumes of agents to spaced sites |
US5798119A (en) * | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
US5728396A (en) * | 1996-02-02 | 1998-03-17 | Alza Corporation | Sustained delivery of leuprolide using an implantable system |
US5985305A (en) * | 1996-02-02 | 1999-11-16 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6117125A (en) * | 1996-05-02 | 2000-09-12 | Cook Incorporated | Method for predetermining uniform flow rate of a fluid from a tubular body and device therefrom |
US5801188A (en) * | 1997-01-08 | 1998-09-01 | Medtronic Inc. | Clonidine therapy enhancement |
US6582418B1 (en) * | 2000-06-01 | 2003-06-24 | Medtronic, Inc. | Drug pump with reinforcing grooves |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007011923A2 (en) * | 2005-07-15 | 2007-01-25 | Microlin, Llc | Fluid delivery device |
US20070025869A1 (en) * | 2005-07-15 | 2007-02-01 | Gordon John H | Fluid Delivery Device |
WO2007011923A3 (en) * | 2005-07-15 | 2007-11-22 | Microlin Llc | Fluid delivery device |
US20080147186A1 (en) * | 2006-12-14 | 2008-06-19 | Joshi Ashok V | Electrochemical Implant For Delivering Beneficial Agents |
US20120288551A1 (en) * | 2011-05-10 | 2012-11-15 | Antecip Bioventures Ii Llc | Implantable Polymeric Device for Sustained Release of Sufentanil |
US9616207B2 (en) | 2014-06-26 | 2017-04-11 | Cochlear Limited | Treatment of the ear |
US10406334B2 (en) | 2014-06-26 | 2019-09-10 | Cochler Limited | Treatment of the ear |
US11213662B2 (en) | 2014-06-26 | 2022-01-04 | Cochlear Limited | Treatment of the ear |
Also Published As
Publication number | Publication date |
---|---|
WO2002085428A3 (en) | 2004-03-11 |
US20020183722A1 (en) | 2002-12-05 |
AU2002307085A1 (en) | 2002-11-05 |
US20030135202A1 (en) | 2003-07-17 |
US6632217B2 (en) | 2003-10-14 |
WO2002085428A2 (en) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6632217B2 (en) | Implantable osmotic pump | |
US6471688B1 (en) | Osmotic pump drug delivery systems and methods | |
US20040015154A1 (en) | Implantable devices with invasive and non-invasive reversible infusion rate adjustability | |
US6464688B1 (en) | Osmotic pump delivery system with flexible drug compartment | |
US6436091B1 (en) | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent | |
EP0808153B1 (en) | Method and device for administering analgesics | |
US7776029B2 (en) | Microminiature infusion pump | |
AU764894B2 (en) | Implantable device for access to a treatment site | |
US4973304A (en) | Device for sustained release of active substance | |
RU2687596C2 (en) | Multiducle devices for performance delivery and methods for drug delivery | |
CN107660138B (en) | Microneedle system for delivering liquid formulations and method for manufacturing microneedle system | |
JP2006524073A (en) | Portable device for the administration of fluids to tissues and tumors by a delivery-enhanced delivery method | |
CA2649098A1 (en) | Apparatus and method for delivery of therapeutic and other types of agents | |
HU221919B1 (en) | Sustained delivery device and system of an active agent using an implantable system and method for producing of the device; a back-diffusion regulating outlet and a semipermeable plug | |
CA2295832A1 (en) | Catheter assembly for percutaneous access to subcutaneous port | |
Aj et al. | Implantable drug delivery system: a review | |
WO2001043528A2 (en) | Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide | |
CN105228671B (en) | Emergency active material supply valve | |
Ranade | Drug delivery systems 4. Implants in drug delivery | |
Lee et al. | Implantable small device enabled with magnetic actuation for on-demand and pulsatile drug delivery | |
US20140221964A1 (en) | Systems and methods for local drug delivery to kidneys | |
Buckles | Biomaterials for drug delivery systems | |
US6616652B1 (en) | Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter | |
Zaffaroni | Applications of polymers in rate-controlled drug delivery | |
US20220134076A1 (en) | Implantable medical device for delivery of pharmacological agents to the deep brain structures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |